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ABSTRACT 
Autologous fat transplantation (AFT) is commonly used as a complementary method to 
enhance breast appearance after breast surgery, radiotherapy and breast reconstruction. Some 
of the indications for AFT to the breast are contour irregularities, volume deficits, chronic 
wounds, soft tissue indurations and scarring. Although AFT is well established with the 
primary aim with AFT is to enhance the patient’s satisfaction, research on patient perceptions 
is sparse. In the 1980s the American Society of Plastic Surgeons (former American Society of 
Plastic and Reconstructive Surgeons) expressed the concern that AFT could lead to false-
positive radiological findings that subsequently would lead to excessive examinations. In 
2009 they requested more studies on AFT to breast cancer patients. Apart from using 
autologous fat as a filler and to soften the breast tissue, AFT can be used to mitigate 
radiation-induced fibrosis and dermatitis. The effect of AFT on radiation-damaged tissue is 
well described clinically, but the biological processes behind the effects are still unknown. 
These issues were also studied in the present research. 
 
A retrospective study (I) was carried out on 43 patients using a study-specific questionnaire 
to assess their perceptions of the results of AFT. Post-operative complications were also 
recorded. The patients reported overall good results and only one minor complication was 
found in all patients.  
In a prospective case-series (II) patient-reported outcomes were assessed in 48 patients using 
a study-specific questionnaire and the 36-Item Short Form Health Survey (SF-36), before, 
and up to two years after AFT. Sixteen of the 20 items in the questionnaire were significantly 
improved two years post-operatively, including pain, scars, appearance and softness of the 
breast, as well as inclination to perform physical activities in public areas. The scores 
obtained with SF-36 concerning health related quality of life did not change after AFT, and 
did not differ from a Swedish reference population.  
In the third study (III), 44 patients underwent mammography and ultrasound before and one 
year after AFT. Assessment was carried out by experienced radiologists. No difference in the 
overall assessment (BI-RADS score 2) could be seen. AFT was found to significantly 
increase the number of breasts with oil cysts, where the breasts with oil cysts had been 
transplanted with larger volumes of fat.  
Finally, gene expression in adipose tissue was investigated with microarray technique and 
Hallmark gene set enrichment analysis (IV). Biopsies were taken from the adipose tissue of 
the irradiated breast and the contralateral non-irradiated breast of ten women before AFT. 
Biopsies were also taken bilaterally one year after AFT of the irradiated breast. Among the 
3000 most differentially expressed genes comparing irradiated and non-irradiated biopsies 
before AFT, 45 enriched pathways were found. After AFT to the irradiated breast, 575 of the 
3000 previously differentially expressed genes were reversed in the irradiated and AFT 
treated adipose tissue, and thus affected by AFT. Among these 575 genes, 13 pathways were 
identified, all of them also found in the pre-operative analysis. The leading canonical 
pathways in the two analyses were interferon gamma response, hypoxia and epithelial 
mesenchymal transition. 
 
The conclusions drawn from these studies are that AFT was perceived as a good 
complementary method of treatment by the patients, who experienced improvements in 
several aspects, and that AFT has no or little negative effects on post-operative radiological 
assessment. Furthermore, may AFT reverse differential gene expression in genes involved in 
inflammation, hypoxia and fibrosis that could have been caused by radiotherapy.   
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1 THE HISTORY OF AUTOLOGOUS FAT 
TRANSPLANTATION 
Various terms have been used to describe autologous fat transplantation (AFT) over the years, 
including lipofilling, lipomodelling, fat grafting and fat transfer.  The history of AFT dates back 
to the late 19th century, when the German surgeon Gustav Adolf Neuber (founder of the first 
aseptic hospital) injected adipose tissue to treat scars in the eye region. Many attempts were 
subsequently made to transplant small fat biopsies underneath the skin, but with poor results 
due to reabsorption and fibrosis (1). In 1983, Illouz described a technique in which fat tissue 
was harvested by suction-assisted lipectomy (2). Bircoll described a similar method of 
liposuction in 1987, and claimed to have taught Illouz the technique in 1984 (3, 4). However, 
reabsorption continued to be a significant problem. A decade later, Sidney R. Coleman 
described a technique in which the lipocytes were better preserved by harvesting under a low 
negative pressure, centrifugation of the aspirate to remove oil and blood, and injection of the 
lipocytes in multiple layers and narrow tunnels to enhance the diffusion of nutrients into the 
transplants (5-7). This technique is still the dominant one today, although some modifications 
have been made to fat harvesting and purification. However, in 1987, the American Society of 
Reconstructive and Plastic Surgeons (today American Society of Plastic Surgeons, ASPS) 
expressed the concern that the use of AFT in breast augmentation would lead to scarring and 
calcification that could lead to difficulties in detecting early breast cancers or false-positive 
findings in mammography, leading to increased breast biopsies being performed for benign 
conditions (8). This started a debate on the safety of AFT in the breast, but surgeons continued 
to use and study the method. In 2009, the ASPS published a new report. Their conclusion 
regarding safety was; “based on a limited number of studies with few cases, there appears to be 
no interference with breast cancer detection; however, more studies are needed to confirm these 
preliminary findings”. In the light of this, the work described in this thesis was initiated.  
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2 BACKGROUND 
2.1 BREAST CANCER AND ITS TREATMENT 
Considerable developments have taken place in the treatment of breast cancer. In the late 19th 
century, William Halsted performed radical mastectomies removing the whole breast, axillary 
lymph nodes, and also the underlying pectoral muscles (9). This remained the predominant 
method, with minor adjustments, until 1972, when John Madden described modified radical 
mastectomy, in which both pectoral muscles were preserved (10). This technique is still used 
today. Breast-conserving surgery (BCS) was developed in parallel, and is since the late 20th 
century a well-established and safe technique when used in combination with post-operative 
radiotherapy. BCS has also developed, and today oncoplastic techniques are commonly used 
to optimise the aesthetic outcome. In addition to surgery, medical treatment has steadily 
gained ground and is now an integral part of breast cancer treatment. 
 
During the 1980s, guidelines for breast cancer treatment were formulated in most of the 
health care regions in Sweden. In 2000, the Swedish Breast Cancer Group (SweBCG) 
developed the first evidence-based national guidelines which, in a later version (2014), were 
adopted as the Swedish National Breast Cancer Management Programme (11). This 300-page 
document is continuously revised by leading researchers and clinicians to ensure that it is 
always up to date and that new evidence is introduced. 
 
2.1.1 Breast cancer epidemiology and prognosis 
Breast cancer is the most common cancer affecting women worldwide. In 2016 the incidence 
was 152.7 per 100 000 women in Sweden, and it is increasing yearly (12, 13). The prevalence 
in 2016 was 105 825 (women) (13). The prognosis is good in many countries, but varies 
globally (11, 14, 15). In Sweden, the 5-year survival is 83%, and was unchanged for all 
patients diagnosed between 2009 and 2012 (16). 
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2.1.2 Diagnosis 
2.1.2.1 The Swedish screening programme 
The Swedish National Board of Health and Welfare recommends that all Swedish women 
aged 40-74 should be offered mammography every 18-24 months as part of a national breast 
cancer screening programme (17). The screening programme is considered to reduce breast 
cancer mortality by 15-25% in the whole population, and even more in those participating in 
the screening programme (11, 18, 19). However, screening for breast cancer is not 
uncontroversial, and it has been criticised for overdiagnosis (19). 
 
2.1.2.2 Triple assessment 
When a woman presents with a lump in her breast, it is investigated by triple assessment 
which comprises clinical examination, biopsy and imaging. A clinical breast examination 
involves a systematic physical examination of the chest, including breasts, nipples, axillae 
and the supraclavicular spaces. In Sweden, fine-needle aspiration cytology (FNAC) is 
standard in the investigation of breast lumps, and in most cases this is deemed sufficient pre-
operatively if the other two cornerstones in the triple assessment are unambiguous. If the 
diagnosis is uncertain, further investigation of the tumour with a core needle biopsy is 
recommended (11). If neoadjuvant treatment is considered core needle biopsy is required. 
 
Radiological examination combined with cytology is the most important investigation. The 
sensitivity is 85-90% but decreases with increasing density of the breast since a higher 
density makes the detection of a tumour more difficult (11, 20). High-density breasts also 
have a higher risk of cancer (21). The natural development of breast tissue is from a high 
density (glandular tissue) in young fertile women, to lower density (fatty tissue) in 
postmenopausal women. In Sweden, a system similar to the Breast Imaging Reporting And 
Data System (BI-RADS) (22) is used to classify and code the images and findings on a five-
level scale (Table 1). BI-RADS can also be used to determine a score for the entire 
mammogram and to classify the density of the breast. Clinical mammography also plays a 
major role in the surveillance after breast cancer treatment. Ultrasound is the method of 
choice in younger women (<30 years), or if the woman is breast-feeding or pregnant. It is 
also widely used as a complement to mammography, especially when the mass is non-
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palpable. As in all ultrasound examinations, the specificity is highly user dependent. In 
Sweden, magnetic resonance imaging (MRI) is generally used only in special cases, for 
example, if the patient has a palpable mass but no mammography or ultrasound findings, or 
in patients with a high hereditary risk of breast cancer. Galactography can be used to examine 
the milk ducts if the patient presents with nipple discharge. 
 
Table 1. Scoring system used in Sweden for classification of images of the breast 
Code Interpretation 
1 Negative/Normal breast 
2 Benign finding 
3 Probably benign finding 
4 Suspicion of malignant finding 
5 Radiological malignant finding 
 
2.1.3 Treatment 
2.1.3.1 Systemic treatment 
Chemotherapy can be given in addition to surgery to improve survival. Historically, it has 
been given as an adjuvant treatment, but this practice has changed over recent years. 
Neoadjuvant chemotherapy is recommended if the patient presents with locally advanced 
tumours. It can also be given to shrink a resectable tumour, thereby avoiding mastectomy. In 
2015, 19% of chemotherapy was neoadjuvant, although the variation was considerable (4-26) 
throughout the country. Depending on the protocol, a 1.4-13% absolute reduction in breast-
cancer-specific mortality has been reported (11). 
 
All patients with oestrogen receptor positive (ER+) carcinomas (about 85%) should be 
offered anti-hormonal treatment. Tamoxifen is a selective oestrogen receptor modulator, and 
has been shown to reduce the absolute risk of recurrence and breast-cancer-specific mortality 
by 13.2 and 9.2%, respectively after 15 years when administered for five years (23). 
Tamoxifen can be given to pre- as well as postmenopausal women. Aromatase inhibitors on 
the other hand, reduce the non-ovarian oestrogen production in the body, and are therefore 
only effective in postmenopausal women whose ovarian oestrogen production has ceased. 
Aromatase inhibitors have a slightly better effect on both recurrence and mortality than 
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tamoxifen in this group (11). Ovarian suppression can be obtained either by surgery, or by 
repeated injection of a hormone agonist, the latter only having an effect in premenopausal 
women. The effect on survival and recurrence has not been fully investigated, but depends on 
several factors, including other therapies (11, 24, 25). 
 
Trastuzumab is an antibody that binds to the HER2 oncogene receptor, which is expressed on 
tumour cells in approximately 15% of breast cancer tumours. It has been estimated that the 3-
year overall survival and recurrence-free survival can be increased by 9 and 11%, 
respectively, when combined with adjuvant chemotherapy (11). 
 
2.1.3.2 Breast surgery  
Historically, mastectomy was the gold standard. In Sweden, the current recommendation for 
mastectomy is unifocal or multifocal tumours that cannot be radically excised with 
cosmetically good results. Mastectomy is also recommended if the patient declines BCS, if 
there are contraindications to RT, or if the patient has a local recurrence and has previously 
been treated with BCS and RT (11). All methods of breast surgery are under continuous 
development, and during recent years nipple-sparing mastectomy has been used more 
frequently in selected patients without jeopardizing oncological safety (26). Today, the most 
common surgical method in Sweden is BCS. This is a method in which only the part of the 
breast containing the tumour is excised. In 2017, 83% of Swedish patients with small 
invasive breast cancer tumours without distant metastases underwent BCS (16). This method 
requires RT to reduce the risk of local recurrence (11, 27). It has been shown that the 
patient’s HRQoL is better after BCS than after mastectomy, and that more radical excision 
seems to have a negative impact on the patient’s satisfaction with the outcome (28, 29).  
 
Techniques that combine oncological safety and reconstructive plastic surgical methods to 
achieve a good post-operative aesthetic result are called oncoplastic breast surgery. These 
techniques allow the excision of larger tumours without risking the patient’s safety or the 
aesthetic result. These methods can be regarded as a third alternative when BCS is not 
appropriate and mastectomy is not necessary (30), and are carried out at the specialist breast 
units in Sweden. A common method is to combine BCS with a contralateral breast reduction 
to achieve better post-operative symmetry. Frequently used techniques for tumour excision 
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include round block, or various techniques for reduction mammoplasty (29, 31, 32). Other 
examples are batwing mastopexy and abdominal advancement flaps (33, 34). 
 
Women with a significantly increased risk of breast cancer can be candidates for bilateral 
risk-reducing mastectomy (35, 36). The indications for surgery are being a carrier of the 
breast cancer genes (BRCA) BRCA-1 or BRCA-2, or having a family history indicating an 
autosomal dominant inheritance of breast cancer (11). 
 
In addition to breast surgery, sentinel lymph node biopsy is performed in women with 
invasive cancer without any signs of axillary metastasis. The sentinel lymph node is the 
lymph node (nodes) that is first in the node chain to drain the breast tumour. It is normally 
located in the ipsilateral axilla, but can be located parasternally in the internal mammary 
chain. The latter is not routinely explored as it is surgically demanding and leads to additional 
scars and morbidity. A blue dye and a radioactive isotope (lymphoscintigraphy) are injected 
either superficially into the subareolar plexus over the tumour, or deep into the glandular 
tissue (37). Sentinel nodes are identified visually by the injected dye and acoustically by the 
signal from a gamma probe. The surgeon extirpates the nodes that are blue, are identified by 
the gamma probe, or have pathological features. The Swedish National Breast Cancer 
Management Programme recommends the extirpation of a maximum of four nodes. The 
nodes are sent for histopathological examination. Supplementary axillary surgery may be 
required if the tumour has metastasised. Sentinel node biopsy indicates the cancer stage. 
 
2.1.3.3 Radiotherapy  
Radiotherapy (RT) is recommended for almost all women who have undergone BCS to erase 
microscopic tumour foci, which may remain in the breast. RT reduces the risk of local 
recurrence to an acceptable level compared to mastectomy. The absolute reduction in the 10-
year risk of first recurrence is 15.7%, and the reduction in the 15-year risk of breast-cancer-
specific death is 3.8% (38). Previously no difference in overall survival has been found 
between BCS with or without RT, and mastectomy (27). However, in a multicentre study it 
has recently been shown that BCS and RT was superior to mastectomy regarding both overall 
survival and breast-cancer-specific survival (39). Depending on tumour stage, RT can also be 
recommended in mastectomised patients to reduce the risk of recurrence. However, the 
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evidence for RT in mastectomised patients is not as strong as for those undergoing BCS. The 
irradiation dose and target of irradiation have also been modified over the years. The current 
standard dose in Sweden for N0 tumours (no metastases) is 40 Gy in 15 fractions, given as 
five fractions per week. Additionally, patients ≤50 years old receive a 10-16 Gy boost, at 2 
Gy per fraction. The dose for pN+ tumours is generally 46-50 Gy in 25 fractions. Women 
≤50 years also receive an additional 10-16 Gy boost after BCS (11). 
 
Side effects of radiotherapy – radiodermatitis and fibrosis 
RT has been part of cancer treatment since the beginning of the 20th century, and is an 
important part of breast cancer treatment. Its side effects are well known, and range from 
increased mortality from lung- and heart disease (11, 38) to systemic effects such as fatigue 
and sleep problems to local symptoms (40, 41). The severity of the side effects varies with 
dose, the number of fractions and the area treated, as well as intrinsic properties such as 
connective tissue diseases (42). In addition, physical reactions may increase over time (43).  
 
Radiodermatitis is a common problem. Acute symptoms appear within 90 days of initiating 
therapy, and normally resolve in a few weeks. Nearly all patients exhibit acute skin reactions 
resulting from RT, but about half of the patients report skin reactions and pain up to six 
months after treatment (40). The symptoms can be very mild, such as erythema, and increase 
with irradiation dose, including dry skin, hair loss, dry desquamation, moist desquamation 
and even ulceration (41). Chronic radiodermatitis can appear early or up to years after 
completing RT. Clinical manifestation of chronic radiodermatitis includes atrophy, 
telangiectasia, pigmentation changes, radiation-induced fibrosis (induration and thickening of 
the dermis), ulceration and necrosis (44).  
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Figure 1. Pathogenesis of radiation-induced fibrosis. 1) Cell damage caused by ionizing radiation 
leads to the outflow of chemokines. 2) Neutrophils, lymphocytes and monocytes migrate to the site. 
Macrophages recruit stromal fibroblasts and stimulate differentiation of circulating mesenchymal 
stem cells to fibroblasts. 3) Macrophages initiate differentiation of circulating fibrocytes through 
epithelial mesenchymal transition, and development of the recruited and differentiated fibroblasts 
into myofibroblasts. 4) The myofibroblasts proliferate and surplus deposition and decreased 
degeneration of extracellular matrix results in fibrosis with reduced vascularity and a lack of cells. 
(Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer Nature, Journal of Cancer 
Research and Clinical Oncology, Radiation-induced fibrosis: mechanisms and implications for therapy, Straub J, et al., 
Copyright Clearance Center’s RightsLink® 2015) 
 
Radiation-induced fibrosis (RIF) is the main cause of morbidity after RT in all organs. A 
wide range of genetic variations can predispose a patient to RIF, and this may be the cause of 
sustained pathology in the otherwise healthy tissue surrounding the treated tumour area. 
However, the underlying biological reactions are not fully understood (45). A schematic 
overview of the RIF process is illustrated in Figure 1. A serious reduction in proliferating 
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cells and a significant increase in apoptotic stromal vascular faction (SVF) cells, as well as a 
reduction in the proliferation and differentiation ability of non-haematopoietic progenitors of 
the SVF in irradiated subcutaneous fat in mice have been shown (46). Irradiation also affects 
a wide range of cellular structures directly by disrupting them. As a result, the cells release 
chemoattractants that induce inflammation. Hypoxia is considered a distinct feature of RIF 
and is caused by vasculopathy and is also correlated to perivascular matrix deposition and 
induction of extracellular matrix synthesis (47-52). Vasculopathy and hypoxia intensify tissue 
damage and inflammation. Neutrophils are the quickest to respond to damaged cells and 
further exacerbate the inflammatory response by releasing chemokines, cytokines and growth 
factors. Cytokines promote the differentiation of macrophages that recruit fibroblasts, directly 
and indirectly via differentiation of mesenchymal stem cells (MSC). Furthermore, 
macrophages stimulate the differentiation of fibroblasts to myofibroblasts directly and 
through epithelial mesenchymal transition (EMT). Myofibroblasts produce excess collagen, 
fibronectin and proteoglycans, leading to fibrosis and rigidity of the tissue. The immense 
collagen production reduces vascularity and causes ischaemia, which may lead to loss of 
function, atrophy and necrosis (42, 53). In parallel with this, irradiation also causes 
intracellular generation of reactive oxygen species (ROS), which can initiate a series of 
reactions causing damage to DNA, proteins and lipids. The release of ROS disturbs the 
normal oxidative metabolism, giving rise to associated chronic inflammatory responses. The 
formation of free radicals occurs not only immediately after irradiation, but can continue for 
several months. Oxidative reactions take place not only in non-irradiated neighbouring cells, 
but surprisingly, also in the cells’ progenies and the neighbouring cells’ progenies, causing 
long-lasting damage (54). The inflammatory response and ischaemia that cause tissue damage 
are often compared with chronic inflammation and a disturbed wound healing process (42, 
53, 55, 56). Chronic inflammation, fibrosis and the ischaemic environment make the tissue 
vulnerable, and are important factors contributing to the clinical effects of RT described 
above, that make surgery more challenging.  
 
RT and chronic radiodermatitis are known to have a negative impact on the complication 
rate, reconstruction failure rate and aesthetic result after breast reconstruction (57-59). 
Contour differences, breast oedema, capsular contracture and mammillary deviation are 
common complications (60, 61). It has been shown that patients who have undergone RT 
report poorer outcome and satisfaction after breast reconstruction than those who have not. 
Patients who have undergone RT may also experience reduced psychosocial well-being and 
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sexual well-being over time (62). In contrast, a meta-analysis of pooled data from 
observational studies on women who had undergone immediate autologous breast 
reconstruction with or without post-operative RT, revealed no significant difference in 
complication rate or revisional surgery. However, the fat necrosis rate and loss of volume was 
higher in patients who had received RT (63). Longo et al. found that irradiated patients 
needed significantly more AFT procedures with smaller fat volumes as a result of post-
irradiation conditions than non-irradiated patients undergoing total breast reconstruction with 
AFT. The total aesthetic score and skin texture were also superior in the non-irradiated group 
(64). RT thus seems to have a negative impact on the efficiency of AFT. 
 
2.2 BREAST RECONSTRUCTION 
History of breast reconstruction started before Halsted’s mastectomies, with attempts to 
correct breast deformities using both flaps and autologous transplantation of lipomas to the 
breast (65). The real breakthrough came in 1964 with the first silicone implant (66). A few 
years later, the predecessor to the modern expander prosthesis was invented (67), and in the 
1980s Becker introduced detachable inflation domes (68) and the expander could thus be left 
in place. Initially, the implant was placed subcutaneously or pre-pectorally, but the technique 
was modified at the beginning of the 1980s due to high rates of capsular contracture, and the 
implant has since then been placed sub-muscularly, with better results. Recently, some 
surgeons have argued to again place the implant pre-pectorally in selected patients (69). 
Different implant surface textures have been tried to avoid capsular contracture, with various 
results (70). Many local flaps have been tried, and the use of abdominal tissue was first 
described in 1979 (65). Development has been rapid towards more complicated methods, and 
today free flaps and microsurgical procedures are frequently used to create new breasts. AFT 
is an important tool in breast reconstruction to further enhance the outcome, usually as a 
complementary procedure to achieve a better result.  
 
According to European guidelines, “a unit team must provide breast surgical reconstruction” 
for patients not suitable for BCS and patients with extensive local disease (71). 
Reconstruction can be performed either immediately after mastectomy or at a later stage 
(delayed). Between 2014 and 2017, 30% of all mastectomised patients in Stockholm 
underwent immediate reconstruction (16), the national rate was 11%, but is slowly increasing 
(16, 72). Delayed breast reconstruction is more common, and is carried out about 1-2 years 
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after the initial cancer surgery. Delayed reconstructions are not registered in Sweden and 
hence no rates are available. The indication for delayed reconstruction is the patient’s wish. A 
breast reconstruction can make life easier (reducing problems associated with poor fitting of 
clothes or an external prosthesis), and improve the patient’s satisfaction with her breasts, 
together with her sexual and physical well-being (73, 74).  
 
2.2.1 Implants  
Depending on skin access and remaining breast volume, either a permanent implant or an 
expander (adjustable) implant, can be used (Figure 2). The implant is usually placed in a sub-
muscular pocket created by releasing the pectoralis major and serratus anterior muscles. 
Expander implants are frequently used in breast reconstruction. This involves a two-stage 
procedure in which the expander is inserted during the first operation. The expander, and thus 
the tissue, is then gradually expanded with saline via a subcutaneous injection dome over a 
period of several weeks. The expander can be replaced by a permanent prosthesis when 
expansion is completed. Permanent expanders can also be used, and then only the injection 
dome is removed after expansion. Breast reconstruction with implants has several 
advantages. In contrast to flaps, there is no problem associated with skin colour matching, no 
donor site morbidity, and the sensibility is better preserved than with free flaps. The method 
may be done as day surgery, but more often as an inpatient procedure requiring a few days 
hospital stay. The disadvantages are a risk of capsular contraction (cumulative incidence 8-
16% in 3-6 years), which can be more than doubled in combination with irradiation (which is 
a relative contraindication), and a high risk of reoperation (cumulative incidence 27-52% in 
3-6 years) (61, 75, 76). The breast will not be as soft as the body´s own tissue, and there is a 
risk of a less natural appearance (61). Additional surgery is often required on the contralateral 
breast to obtain better symmetry. AFT can be used to correct rippling and irregularities 
caused by the implant. Implants can be combined with other types of autologous 
reconstruction methods, and can be used in both immediate and delayed reconstructions. 
Complementary methods using an acellular dermal matrix or autologous dermal grafts are 
sometimes used to create a better implant pocket (77).  
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Figure 2. Breast prostheses. Expandable prosthesis with injection dome to the left. The injection 
dome is placed subcutaneous Permanent prosthesis to the right. (Anna Lindegren 2018) 
 
2.2.2 Flaps  
There are two major types of flaps; pedicled and free flaps. Pedicled flaps are connected to 
the donor site by blood vessels and often nerves. In the case of free flaps, blood vessels, and 
sometimes nerves, are sutured to recipient vessels and nerves, at the reconstruction site. Flaps 
used in breast reconstruction consist of skin, subcutaneous fat, fascia and muscles in various 
combinations. Flaps are used to provide volume, surface and healthy tissue to a breast with 
tissue deficiencies, irradiated tissues and implants in need for soft tissue coverage. 
 
Small pedicled flaps are usually used to add soft tissue to cover implants. The surgical 
procedure is less complex than that with free flaps, and the donor site scar is often less 
prominent (78). The latissimus dorsi (LD) flap is often used for reconstruction of irradiated 
breasts. The LD flap was first described in 1896 by the Italian surgeon Iginio Tansini, but 
became widely known after being re-described by Olivari in 1976 (79). The LD flap is a 
musculocutaneous flap in which part of the LD muscle is dissected together with 
subcutaneous fat and often a skin island. It is rotated and tunnelled with intact blood supply, 
and sometimes also nerves, and placed in the lower pole of the breast. An LD flap is usually 
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combined with implants and, in recent years, also with AFT (80, 81). The lateral 
thoracodorsal flap (in Sweden called the “Gothenburg flap”) is a fasciocutaneous flap in 
which tissue from a horizontal triangle extending laterally is transposed vertically, the base 
being in the anterior axillar line, to add tissue to the breast. An implant is placed sub-
muscularly (82). This flap can be useful in some cases, although it is not frequently used. The 
transverse rectus abdominis myocutaneous (TRAM) flap is an abdominal flap based on the 
deep inferior epigastric vessels and is raised with an elliptic incision from hip to hip in the 
lower part of the abdomen. The TRAM flap contains skin, the subcutaneous fat layer and the 
rectus abdominis muscle or part of the muscle (muscle-sparing TRAM flap). The pedicled 
flap is tunnelled under the skin to the chest. When the donor site is closed the umbilicus must 
be transpositioned (83). The advantages of the TRAM flap are the possibility to create a 
whole new breast with a natural shape, which varies in size if the patient gains or loses 
weight, and the breast feels natural. Pedicled TRAM flaps are seldom used in Sweden due to 
abdominal wall donor site morbidity and muscle weakness. 
 
A range of free flaps with different origins (abdominal, gluteal and thigh etc.), can be used in 
breast reconstruction; the most frequently used in Sweden being an abdominal flap, the deep 
inferior epigastric artery perforator (DIEP) flap. The DIEP flap is based on the deep inferior 
epigastric vessels, which can be anastomosed to the internal mammary vessels in the chest 
(which requires microsurgery) sometimes after a small portion of rib and cartilage is excised, 
or to a vessel in the axilla (84). The superficial inferior epigastric artery flap is based on the 
superficial inferior epigastric vessels, as the name implies. Both flaps contain skin and the 
subcutaneous fat layer, and are raised in the same way as the TRAM flap (which can also be 
a free flap) with an elliptical incision and umbilicus transposition, but with preservation of the 
rectus muscle. The advantages are the same as with the pedicled TRAM flap, but without 
muscle weakness, and there is no need for tunnelling under the skin. Unfortunately, most of 
the sensibility is lost with free flaps as the nerves are cut.  
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2.3 METHODS OF EVALUATING THE RESULTS OF BREAST 
RECONSTRUCTION 
2.3.1 Patient-reported outcome 
With the evolution of modern health care, the patient’s rights and participation in decision-
making have been strengthened. It is now mandatory in Sweden to involve patients in their 
treatment. Patient-reported outcome measures (PROMs), self-assessment surveys assessing 
patient-reported outcome (PRO), are important instruments to measure patients’ perceptions 
of their symptoms and the outcome of their treatment. It has been shown that using PROMs 
in clinical practice improves patients’ satisfaction with care and PRO (85). The PRO is best 
measured using questionnaires to rate symptoms, functioning level, health-related quality of 
life (HRQoL) and sometime also satisfaction with the care given and the care provider. 
Evaluation of the last two is referred to as the patient-reported experience measure. PRO can 
be measured on different levels from general HRQoL to diagnosis-specific symptoms.  
 
2.3.1.1 SF-36 
The 36-item Short Form Health Survey (SF-36) was developed at the end of the 20th century 
in English, and became available in Swedish shortly after. It is used to measure health-related 
HRQoL. The questionnaire contains eight domains: physical functioning, physical role 
functioning, bodily pain, general health, vitality, social functioning, emotional role 
functioning and mental health. In the Swedish version of SF-36, a reference population 
consisting of 8 930 people who lived in seven regions, in 1991-92, is provided. According to 
national registers, those living in the specific urban area of the reference population 
(Gothenburg) have a lower HRQoL than other equally sized communities in Sweden. The 
scores of the SF-36 are values between 1 and 100 for each domain, where 100 indicates the 
highest possible HRQoL in that domain. In addition, two summary scores can be used: the 
physical component summary (PCS) and the mental component summary (MCS) scores (86, 
87). 
 
2.3.1.2 BREAST-Q 
BREAST-Q was the first validated PROM to assess PRO in women who had undergone 
breast reconstruction (88, 89). It first became available in English in 2009. It was translated 
  16 
into Swedish in 2012, but has only been validated for North American women. The 
questionnaire consists of a pre-operative survey form and a post-operative survey form, 
containing questions on six domains: psychosocial well-being, physical well-being, sexual 
well-being, satisfaction with breasts, and satisfaction with outcome. Moreover, it also 
includes items on satisfaction with care. The scores are presented as a value between 1 and 
100 for each domain, where 100 indicates the highest possible HRQoL for that domain. 
2.3.1.3 Other PROMs 
The most commonly used general questionnaires in Swedish national quality registries are 
SF-36, RAND-36 (90) and EQ-5D (91). RAND-36 is a free of charge questionnaire based on 
SF-36 with the same questions. RAND-36 is translated into Swedish (92). EQ-5D is an 
instrument for assessing general HRQoL in five domains: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. A new questionnaire for women undergoing breast 
reconstruction, QLQ‐BRECON23, has recently1 been developed and internationally validated 
by the European Organisation for Research and Treatment of Cancer (93). Most people are 
unknowingly familiar with Likert scales, which are widely used in surveys and 
questionnaires, and the possible responses are typically “strongly agree”, “agree”, “neutral”, 
“disagree” and “strongly disagree” or numbers for example 1-5. Opinions differ as to whether 
a Likert scale should be treated as an ordinal scale or an interval scale, or whether it is 
preferable to use mean values or medians when analysing the responses. The use of a Likert 
scale in a one-item survey is not recommended as it is considered not to be capable of 
assessing the hypothesis (94, 95). 
 
2.3.2 Aesthetic outcome 
Evaluating the aesthetic outcome is difficult and there is a high risk of subjectiveness 
regardless of how the assessment is carried out. In the light of PRO, it is debatable whether 
the opinion of an external assessor is of any interest at all (96). Moreover, it has been reported 
in a number of studies that there are discrepancies between the opinions of surgeons and 
patients, as well as between surgeons (78, 97-101). There are thus few analytical reports. 
 
                                                
1 E-published November 8 2017 
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When reporting the aesthetic outcome, tools such as the visual analogue scale, VAS, and 
three- to seven-point Likert scales are often used. Another option is to use ordinal rating 
scales, e.g. excellent, good, fair or poor. The drawbacks of using this type of scale are that the 
studies are non-reproducible, and their results are not comparable. Moreover, it is difficult to 
analyse the output, and there are different opinions as to whether the numerical values should 
be treated as ordinal or interval. The Breast Cancer Conservative Treatment. cosmetic results 
(BCCT.core) software offers a method based on the same principles as subjective ratings, and 
has been validated for BCS. The intention of this software is to provide an objective method 
for the assessment of the aesthetic outcome (102).  
 
Anthropometry involves linear measurements between anatomical landmarks. In the case of 
breast surgery, these measurements are thought to facilitate pre-operative planning, in an 
attempt to obtain “normal” breasts after breast surgery or breast reconstruction. It can be used 
for pre- and post-operative comparison. The measurements were developed by Jack Penn in 
1955, and were based on 20 women who were chosen among 150 volunteers because they 
had “aesthetically perfect breasts” (103).  New “normal values” were published in 1986, 
based on 55 American women aged 18-31, and in 1997 measurements of “aesthetically 
perfect breasts” were reported for 50 Caucasian, nulliparous women aged 17-38 (104, 105). 
Anthropometric measurements can also be made on photographs. The advantages are that the 
image does not change, and retrospective evaluation is possible. On the other hand, some 
anatomical landmarks may not be visible on photographic images, and there are no widely 
used standardised protocols for this method. 
 
It appears that we are moving towards objective measurements with three-dimensional (3D) 
measurements. Early measurements were performed with computerized tomography (CT) 
and MRI. The accuracy of these techniques was good, but they are time consuming for both 
the patient and the radiologist. In addition, MRI scans are expensive and CT entail radiation 
(106). Today, 3D surface imaging can be performed by laser scanning and by photography. 
Both methods rely on manually placed landmarks, and even small changes in position 
between imaging sessions make the calculations more difficult (107). The costs for 3D 
measurements are still high, but are decreasing (108). 
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3 AUTOLOGOUS FAT TRANSPLANTATION TO THE 
BREASTS 
3.1 BACKGROUND 
AFT is a widely used method for enhancing the aesthetic and functional outcome in various 
regions of the body. It can be used to rejuvenate areas of the face and hands, and to augment the 
breasts, gluteal region and genitals. However, it is also used to treat burn scars, chronic wounds, 
post-operative pain and radiation-damaged areas, and for the stabilization of vascular pedicles 
(109-115). In reconstructive plastic surgery, one main field of application of AFT is as a 
complement to, or as a part of, breast reconstruction after breast cancer surgery. It is minimally 
invasive and has low morbidity, and there is no scarring as is the case following reconstruction 
with flaps. Another positive side effect for many patients, is that liposuction is performed often 
on the abdomen or thighs. AFT is a technique with which the surgeon can correct minor flaws, 
as well as treat large areas of radiation-induced malformations. 
 
Although AFT is a widely used method, many studies on AFT do not have a robust study 
design, the evidence level is low, and often statistically underpowered. Very few clinical trials 
have been conducted on AFT and few focusing on one particular area rather than many 
different. Moreover, most of the studies are not reproducible, and definitions of similar 
outcomes diverge. An explanation of the limitations may be that many surgeons have no 
incentive to properly assess AFT because of the positive features and the few surgical 
complications. Moreover, since AFT differs profoundly from other reconstructive methods and 
is difficult to compare with other methods, there is no truly suitable control group. A review of 
the current literature on AFT in breast reconstruction is given below.  
 
3.2 SURGICAL TECHNIQUE OF AFT 
The method comprises three stages: fat harvesting, fat preparation and fat injection illustrated in 
Figure 3. First, the donor site should be chosen. This is normally the location with the greatest 
excess fat tissue. Studies have been carried out to investigate the best donor site for AFT with 
regard to tissue viability, however, no differences were found (116, 117). A few studies have 
reported a higher yield of AT-MSC in fat harvested from the abdomen (118, 119). None of 
  20 
these studies considered the clinical outcome. The most common donor location is the 
abdomen; while the knee, thigh and flank are also frequent sites (120). The fat is harvested with 
either wet or dry technique. In the wet technique, a tumescent solution is infiltrated into the 
subcutaneous adipose tissue of the donator site; to provide local anaesthesia and to facilitate fat 
removal (121). In the dry technique the infiltration is not performed (122). No substantial 
differences in adipocyte viability have been reported between the techniques, however, it has 
been suggested that the wet technique may offer a slight improvement in cell viability, but there 
is no consensus (116, 123). Harvesting can be performed by syringe aspiration, suction by hand 
or with suction-assisted lipectomy, all of which have been reported to have comparable 
adipocyte viability (116, 123). The harvested fat is a mixture of viable cells, oil, blood and, 
when used, tumescent solution.  
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Figure 3. Autologous fat transplantation (AFT). The technique includes three steps: harvesting by 
liposuction; processing; and injection into the recipient area. a–c examples of the spectrum of 
indications for AFT treatment. a) Scar retraction after breast conserving surgery and sometimes 
radiotherapy. b) AFT after reconstruction with flap. b) Rippling over implants. (Reprinted by permission from 
Wiley Online Library, The British Journal of Surgery. Meta-analysis of the oncological safety of autologous fat transfer after 
breast cancer. Krastev TK, et al. Copyright Clearance Center’s RightsLink®, 2018) 
 
The harvested material could be injected as is, but it is usually prepared in order to optimise the 
survival of the adipocytes. The aim is to filter or separate the mixture from blood and oil to 
extract the progenitor cells and functional adipocytes. In 2013, only 5% of the members of the 
ASPS used additives. The proportion is probably higher today, but the conventional method of 
preparing harvested fat is to remove the blood, oil and tumescent solution, in one way or 
another. Common methods of preparation are centrifugation, gravity separation, filtration, 
washing with saline or Ringer-Acetate and cotton-gauze rolling (the harvested material is 
poured into a dressing and rolled and massaged gently) (120). There is no consensus regarding 
which method should be used, however, preparing the fat for injection is favourable, regardless 
of the method used (116, 124, 125). When comparing non-processed cells with cells subjected 
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to centrifugation and rolling in cotton gauze in a murine study, Canizares et al. found that 
centrifugation led to a higher proportion of progenitor cells and MSC, while filtering with 
gauze led to more functional adipocytes, higher post-operative secretion of growth factors, 
neovascularization and the highest fat graft persistence (126). Moreover, the fat transplant can 
be enriched before injection. AT-MSC can be isolated and cultivated ex vivo before injection. 
This may increase the survival and quality of the fat transplant (127). A similar approach for 
enrichment is to use the SVF, which contains a miscellany of progenitor cells. These two 
enrichment methods are called cell-assisted lipotransfer and have been shown in a meta-
analysis to significantly increase the fat survival rate in injection volumes <100ml, but did not 
reduce the number of procedures needed (128). Both are known to have regenerative abilities. 
An additive that has been used for enrichment is platelet-rich plasma, but this was not verified 
to be effective (129). 
 
The last stage, injection, is not as disputed as harvesting and preparation. Most surgeons 
transfer the fat to small syringes before injection. The fat should be injected slowly in single or 
multiple layers, depending on the area and indication, using a blunt cannula. It is considered 
that the diameter of the cannula should be at least 2.5 mm (7, 123) (Figure 4).   
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. Figure 4. Fat injection with a Coleman cannula. 
 
3.3 INDICATIONS  
There are many indications for AFT to the breast. Hypoplasia, asymmetry and tissue deficiency 
caused by congenital conditions are some of them (124). In breast reconstruction the main 
indications are asymmetry, tissue defects after breast surgery and RT, deformities, scarring or 
rippling over implants (124, 130). AFT can be used to fill defects, add volume and loosen scars. 
Moreover, it has also been shown in clinical studies that radiation-induced fibrosis, 
radiodermatitis and pain can be ameliorated with AFT (101, 113, 131). Successful whole breast 
reconstructions with AFT only have been reported, but require multiple procedures (132). 
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3.4 COMPLICATIONS 
AFT is a method with few severe complications. The overall complication rate is generally 
below 10%. In a systematic review on breast reconstruction, Agha et al. reported a 
complication rate of 7.3%, fat necrosis being the most common (62% of all complications). 
86% were Grade I according to the Clavien-Dindo2 (133) classification (134). Groen et al. 
reported a complication rate of 8.4%, with palpable nodules being the most common. Cysts, 
haematoma, calcification, striae and fat necrosis, in descending order of incidence, were also 
reported. Less common complications are infections, seroma, pneumothorax and delayed 
wound healing (135). In a systematic review on healthy breasts, the complication rate for 
surgical complications was 15.6%, while for complications associated with radiological 
examination, such as oil cysts, fat necrosis and calcifications that led to biopsies, was 2.2% 
(136).  
 
3.5 PREVIOUSLY PUBLISHED RESULTS 
3.5.1 PROM 
There are few comparisons before and after AFT, or comparisons with control groups. 
However, as mentioned above, it is difficult to define control groups. In a recent meta-analysis, 
Krastev et al. (100) tried to summarise the disparate values from 34 studies, including one 
carried out by our group (137). In an attempt to standardise the results from different studies, all 
the scales were converted into a 10-point scale (continuous data) or dichotomised (categorical 
data). No information was given on results regarding specific questions such as satisfaction 
with size. All the results were transformed into an overall degree of satisfaction. The 
continuous data showed a mean score of 7.4 (95% CI 6.8-8.1) on a 10-point scale, but follow-
up time was unknown. The categorical data showed a degree of satisfaction of 94.3% (95% CI 
89.9-96.9), for a mean follow-up of 1.9 years. The results from BREAST-Q were analysed 
separately, giving a general rating of 73.0 (95% CI 67.7-78.4). No analysis was performed of 
                                                
2 Clavien-Dindo Grade I: Any deviation from the normal post-operative course without the need for pharmacological treatment or surgical, 
endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and 
electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. 
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pre- and post-AFT scores, and it is therefore not possible to draw any conclusions regarding the 
impact of AFT on patients’ satisfaction with the outcome of AFT alone. Neither did they take, 
for instance, bias into account in the exclusion criteria. In one of the included studies the 
surgeon asked two hundred patients at their post-operative visit if they were very satisfied, 
satisfied, partially satisfied or dissatisfied with the outcome (138). All the patients answered 
that they were satisfied or very satisfied. This indicates a risk of systematic bias due to a lack of 
anonymity and a presumed tendency of politeness towards the surgeon.  
 
Until recently, low-quality case series were the only source of information about PRO in the 
context of breast reconstruction with AFT. In 2017, Bennett et al. (139) published the results of 
a multicentre cohort study in which the study population consisted of women presenting for 
breast reconstruction after mastectomy. The cases and controls scored similarly in all four 
reported domains in BREAST-Q: satisfaction with breasts, physical well-being, psychosocial 
well-being and sexual well-being, both at baseline and after two years. One limitation of that 
study was that 18.9% of the controls had undergone AFT previous to the baseline 
measurement. The authors did not quantify the number of procedures or fat volume. Moreover, 
the cases and controls differed in vital characteristics such as RT, reconstruction method and 
whether they had undergone any revisional surgery prior to AFT. It is difficult to draw any 
conclusions from this study, since the groups are not comparable. In the same year, Cogliandro 
et al. (140) published the findings of a non-randomised controlled trial in which irradiated and 
non-irradiated patients who were about to undergo breast reconstruction with permanent 
implants were enrolled. Two groups were formed: those who had undergone AFT one year 
after reconstruction, and those who declined further surgery. The groups were compared with 
BREAST-Q post-operatively. The AFT group scored significantly higher in 12 out of 18 
questions addressing satisfaction with breasts. In questions about physical well-being the AFT 
group reported less pain in the chest area, but no differences in the other parts of the upper 
body. The results of this study indicate that AFT is a good complement affording breasts that 
have been reconstructed with implants a more natural appearance, and reducing pain in the 
region. However, they only measured PRO post-operatively, did not consider multiple testing 
or tested differences in characteristics between the groups. It is therefore impossible to 
determine whether there is a causal link. 
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3.5.2 Radiological imaging after AFT 
Few studies on the radiological aspects of AFT have been published during recent years, 
mainly case reports or case series. A minority included breast cancer patients (141-148). In two 
different reviews, meta-analysis could not be carried out because of the heterogeneity between 
studies, and it was therefore difficult to draw any conclusions (134, 149). 
 
Four reviews (134-136, 149) reported that 13-18% of AFT patients had radiological 
abnormalities, 11.5% needed repeated mammography, and in 2.1-3.7% it was necessary to 
proceed to biopsy of the abnormality. The most common findings were cysts (11.25-26.7%), fat 
necrosis (11.3%), micro- and macro- calcifications (1.6-8.7%), suspicious lumps (5.1%) and 
cancer recurrence (4.2%) (135, 136, 149). It has been reported that larger injected fat volumes 
may lead to more calcifications and oil cysts (150, 151).  
 
Ultrasound is preferred to identify cysts (135, 149, 152), and mammography to identify 
calcifications (135). In a study where palpable masses after AFT were examined with 
ultrasound and compared to histopathological results, it was concluded that ultrasound was a 
reliable method of distinguishing between benign and malignant lesions after AFT (153). 
Furthermore, BI-RADS scores seem to be unaffected by AFT (142, 143, 151, 153). However, 
in one study four of the 39 patients who all hade pre-operative BI-RADS score 1 or 2, had post-
operative BI-RADS score 3 or 4 (154).  
 
The potential increase in the need for radiological examinations after AFT has been assessed in 
a case-control study. The AFT patients had 22% more radiological examinations than the 
controls, but only mammography was significantly more frequent, probably because of the 
small sample size (155). Based on the evidence above, AFT to the breast does not seem to have 
any serious impact on radiological assessment. However, the number of radiological 
examinations may increase due to increased benign lesions. Since ultrasound is safe and cheap 
compared to MRI, and a good tool for examining AFT-induced lumps, it may be the first 
choice when investigating the breast after AFT if a patient presents with a palpable lump. 
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3.5.3 Effect of AFT on irradiated tissue 
3.5.3.1 Clinical effect of AFT on radiation-induced fibrosis and radiodermatitis 
There are several reports on a regenerative effect in tissue treated with AFT in both human and 
animal models (113, 131, 156-158). The LENT-SOMA scale (159) is a tool used to assess 
tissue damage caused by irradiation3. Panettiere et al. reported significantly lower LENT-
SOMA scores for pain, telangiectasia, atrophy, breast oedema and fibrosis after AFT to 
irradiated and reconstructed breasts (131). In a randomised controlled trial on mastectomised 
and irradiated women, pain was significantly reduced, HRQoL increased and scars were 
improved according to the observers, but not the patients in the AFT group (101). Rigotti et al. 
treated 20 patients with LENT-SOMA grade 3 (severe symptoms) or grade 4 (irreversible 
functional damage) with AFT, and managed to decrease the LENT-SOMA scores significantly. 
Four of the patients with pre-operative score of 4 decreased to 0, which means cured (113). 
 
3.5.3.2 Biological effect of AFT after irradiation  
The biological effects of AFT on radiation-damaged tissue have primarily been explored in 
animal models, and are still not fully understood (156, 160, 161). Since the main causes of RIF 
and radiodermatitis seem to be persisting hypoxia and inflammation there are reasons to believe 
that AT-MSC play a key role in the mechanisms of the positive effects of AFT that we see 
clinically (113, 156, 162-164). When injected in mice, human AT-MSC secreted vascular 
endothelial growth factor, especially in a hypoxic environment (165). There are a few animal 
studies in which the effect of AFT to irradiated skin and fat has been studied by analysing 
biopsies. Comparison of AT-MSC-enriched AFT-treated and non-AFT-treated irradiated mini 
pigs, using immunohistochemical analysis of cytokeratin expression showed complete recovery 
of the epidermis in the ACS pigs. Lymphocyte infiltration, a sign of healing, was detected more 
than two months earlier than in the controls. An increase in vascularization was seen after the 
fourth fat transplantation, which was absent in the controls (160). In a murine model, Garza et 
al. injected human fat subcutaneously four weeks after irradiation. They found dermal 
                                                
3  The LENT-SOMA scale scores pain, oedema, fibrosis/fat necrosis, telangiectasia, arm lymphoedema, 
retraction/atrophy and ulcer. Grade 1 includes occasional pain, epidermal ulcers and 10-25% retraction. Grade 4 
includes useless arm, bone exposure and atrophy of the whole breast. 
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thickening, higher collagen deposition and hypovascularity, compared to the non-irradiated 
controls before fat transplantation. Post-transplantation the researchers showed increased 
vascularity (also reported by Luan et al. (164)), and reduced dermal thickening and collagen 
content in the irradiated skin. Vascular density did not reach the levels of the controls, and fat 
retention was higher in the irradiated group (161). The cause of loss of transplant volume seen 
after AFT (166) may be explained by radiation-induced hypoxia in the tissue (162). Electron 
microscopy examination of irradiated tissue has shown radiation-induced ischaemic lesions and 
scleroderma, and a gradual improvement after AFT with normalisation of the microcirculation, 
leading to better hydration and less fibrosis (113). There is still a lack of detailed knowledge on 
genetic changes and molecular modifications.  
 
3.6 ONCOLOGICAL SAFETY 
The oncological safety of AFT has been debated since the ASPS suggested in 1987 that fat 
transplantation could make it more difficult to detect early breast cancer. Since 2009, the ASPS 
has recommended baseline mammography and that surgeons should “exercise caution when 
considering high-risk patients” based on “little or no systematic empirical evidence”. Since 
then, very few clinical studies with a high evidence level have been conducted. However, 
experimental studies examining MSC transplantation in vivo and in vitro have shown that MSC 
promote tumour growth and stimulate an inflammatory microclimate favourable for tumour 
cells in tissues other than breast. On the other hand, other studies have shown that MSC 
suppress tumour formation and induce apoptosis in skin and blood cancers (167).  The evidence 
is also conflicting in breast tissue. MSC and AFT have been shown to have an immuno-
suppressive effect that enables tumour growth and metastasis capacity in murine models and in 
in vitro experiments (168-171). Moreover, it has been suggested that adipose-derived MSC 
(AT-MSC) promote an inflammatory environment that stimulates tumour proliferation (172). It 
has also been shown that MSC do not induce neoplasia in healthy adipose tissue (172). These 
findings have raised concerns that AFT could induce recurrence. No studies have been 
published on the effect of MSC on tumour cells in irradiated breast tissue. However, in a recent 
murine experiment, AFT did not stimulate tumour growth and a reduction in the proliferation 
rate of the tumour cells was observed (173). 
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In a number of clinical studies and systematic reviews, researchers have tried to rebut the 
suggestion that AFT could promote or induce recurrence (134, 135, 145, 149, 174). In 2013, it 
was reported in a systematic review (145), that no inferences could be drawn, even from larger 
studies, because of incomparable patient groups and diverging results. In 2018, Krastev et al. 
(175) published a meta-analysis including their own, at that time point, unpublished results 
(176) and a study assessing recurrence in patients previously reconstructed with DIEP flaps in 
which it is not specified if the fat was injected in the remaining breast tissue or in the flap. The 
mean follow-up time was 5.7 years for all AFT patients, and the disease-free interval in 
matched cohorts was 3.3 years. Meta-analysis of seven matched cohorts showed a difference in 
the incidence rate of LRR of -0.15% (95% C.I. -0.36-0.07) per year. The lower LRR incidence 
rate for AFT patients was not statistically significant (p=0.419). A meta-analysis of unmatched 
cohorts showed a significant (p=0.004) difference in incidence rate of -0.27% (95% C.I. -0.43- 
-0.11) per year, indicating that AFT is protective against LRR. This finding is probably the 
effect of suboptimal study design, with unmatched controls, demonstrating the importance of 
robust study design in research. Moreover, pooled data from case series and cohort studies were 
used to calculate incidence rates. The overall incidence rate was 0.73% (0.56-0.94) per year. 
Meta-analyses of subgroups showed an incidence rate of 0.79% (0.61-1.01) per year in 
mastectomy patients, 0.57% (0.23-1.40) per year in BCS patients, 0.83% (0.63-1.09) per year 
for invasive tumours and 0.45% (0.10-1.89) per year for in situ carcinomas. The last sub-
analysis is particularly important and interesting since a previous matched case-control study 
showed a higher risk of recurrence for in situ carcinomas (177). The same group conducted a 
new case-control study on the in situ patients and found a 5-year cumulative incidence of local 
recurrence of 18% in AFT patients, but only 3% in controls (178). These two studies have, for 
obvious reasons, attracted considerable attention. Recently, the authors published an additional 
case-control study in which no differences were found in ipsilateral breast cancer recurrence, 
lymph node metastasis, distant metastasis, contralateral breast cancer, other primary breast 
cancer or death as a first event. In the discussion, they mention that they found no statistically 
significant difference between cases and controls in an unpublished long-term follow-up of the 
patients in the in situ study. In a case-control study, it was found that the total fat volume did 
not affect the risk for recurrence (179). BRCA carriers who have undergone risk-reducing 
mastectomy and AFT do not seem to have any increased risk of breast carcinomas (180). 
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In conclusion, concerns have been raised that AFT could promote breast cancer recurrence 
based on in vitro studies. Clinical research has not been able to prove or rebut this suggestion. 
Current research indicates that AFT does not seem to induce local or distant recurrences. Since 
randomised controlled trials and cohort studies are not possible, large matched case-control 
studies are still necessary to establish whether AFT could lead to breast cancer recurrence. 
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4 AIMS OF THIS RESEARCH  
The overall aim of this research was to improve our knowledge of the outcome of autologous 
fat transplantation when used as a complementary technique in reconstructive plastic surgery 
in the female breast.  
 
Specific aims of the studies: 
 
 The aims of the first study were to assess the the experiences, and identify possible 
postoperative complications, of the first group of patients’ who had undergone AFT at 
the Department of Reconstructive Plastic Surgery, Karolinska University Hospital. 
 
 The aim of the second study was to assess patient-reported outcome before and after 
AFT and to assess the patients’ health-related quality of life.  
 
 The aim of the third study was to investigate if AFT could hinder future radiological 
assessment of the breast and to evaluate changes in the breast after AFT with the two 
most commonly used radiological methods: mammography and ultrasound. 
 
 The aims of the fourth study were to investigate whether gene expression in adipose 
breast tissue is altered by irradiation, and whether AFT alters gene expression in 
irradiated adipose breast tissue.
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5 PATIENTS AND METHODS 
All the 86 women enrolled in the studies were patients at the Department of Reconstructive 
Plastic Surgery at Karolinska University Hospital. Some women participated in more than 
one study (Figure 5). The majority of the patients (73%) had previously been treated with RT. 
 
 
Figure 5. Number of patients from whom data were analysed in each study, and how the patient 
groups overlap. The total number of patients were 86. Study I: n= 44, Study II: n=48, Study III: n=37 
and Study IV: n=10. 
 
5.1 ASSESSMENT OF PATIENTS’ EXPERIENCE OF AFT AFTER BREAST 
RECONSTRUCTION, AND POST-OPERATIVE COMPLICATIONS 
Patients who had been treated with AFT after mastectomy and breast reconstruction or BCS 
at the department between June 2006 and March 2010 were eligible. Women with at least six 
months follow-up were contacted by post and asked to answer a 12-item questionnaire 
concerning the outcome. Three of the items contained background questions, and in another 
three items, the possible responses were yes or no. Nine items were answered on an ordinal 
scale (much worse, worse, unchanged, better or much better). The items included questions 
on breast consistency, size, shape, sensibility, skin quality, unevenness, and sequelae at the 
donor site. In addition to responding to the questions the patients were able to make 
comments and were asked to describe any problems at the donor site. The senior authors 
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constructed the questionnaire (Appendix 1). It was not psychometrically tested for reliability, 
validity or sensitivity. If a patient did not respond, a reminder was sent after one to two 
months. The medical records of the patients were reviewed to identify any complications 
resulting from AFT. 
 
5.2 ASSESSMENT OF PRO AND HRQOL 
Fifty women who had undergone BCS or mastectomy and delayed breast reconstruction, and 
who presented with poor aesthetic results after surgery and RT, were consecutively enrolled 
in this prospective case series. These patients were included from October 2008, until June 
2013. A flow-diagram of the patients’ participation at different time-points is given in Figure 
6. The patients underwent 1-4 AFT treatments. Two questionnaires were answered prior to 
AFT, and six months, one year and two years after final AFT. 
 
A twenty-item study-specific questionnaire (SSQ) was used (Appendix 2). The SSQ has 
previously been used in studies focusing on other methods of breast reconstruction (181, 
182). It was modified for the evaluation of AFT. The original questionnaire was developed by 
a psychologist, specialised in oncological patients, in association with experienced plastic 
surgeons (73). Sixteen of the items were rated on a seven-point Likert scale, and considered 
as continuous in the analysis. The remaining four items were answered on an ordinal scale 
(not at all, little, pretty much and much). The 16 numerically scored items regards sensitivity, 
symmetry, aesthetic outcome, consequences of breast cancer treatment (pain and softness) 
and practical problems. The four ordinal items cover sexuality and difficulties associated with 
being seen naked. The questionnaire was not psychometrically tested for reliability, validity 
or sensitivity. 
 
The eight domains of SF-36 were used assess the patients’ HRQoL longitudinally and to 
compare with that of an age matched Swedish female reference population. 
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Figure 6. Flow diagram showing patient participation in Study II. Boxes to the left: number of patients 
who completed the study-specific questionnaire at each time point. Boxes in the middle: number of 
patients that participated in the study. Boxes to the right: excluded patients and drop-outs. 
 
5.3 ASSESSMENT OF RADIOLOGY 
The study population of 37 women (44 breasts) was drawn from the study described in Paper 
II. Mammography and/or ultrasound were carried out, a maximum of three months before 
AFT. The patients were re-examined at the planned one-year follow-up. The time point of the 
intended one-year revisit varied depending on the booking schedule. 
 
Breast radiologists assessed the examinations. The assessment was carried out by manually 
counting oil cysts and fat necrosis in the preoperative and post-operative mammograms and 
ultrasound images. The occurrence of calcification and scarring was noted pre- and post-
operatively, as well as the progression of pre-existing calcifications and the regression of 
scarring in the post-operative images. The images were also graded using the BI-RADS score 
and the pre- and post-operative results were compared. In addition, follow-up-time, the 
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volume of injected fat, and age and time from last surgery to first AFT procedure were 
compared among the patients with and without findings for all the parameters. For example, 
age was compared between patients who had oil cysts and those who did not. 
 
5.4 ASSESSMENT OF GENE EXPRESSION ALTERATIONS IN 
IRRADIATED ADIPOSE TISSUE BEFORE AND AFTER AFT 
Thirty irradiated patients were consecutively recruited from the study described in Paper II 
and another study on AFT patients. Adipose tissue biopsies were taken at the same time from 
both the irradiated breast and the contralateral non-irradiated breast, the latter providing an 
internal control. The biopsies were taken before AFT, and about one year after AFT.  
 
5.4.1 Global gene expression profil ing 
Within our cells the compressed drawing of the entire body is contained in our chromosomes. 
The chromosomes are DNA molecules carrying our genes. Each gene codes for one, none, 
several, or a segment of a gene product, most commonly a protein. That process is called 
gene expression. All genes are not expressed (activated) at the same time and some genes are 
never expressed, moreover the genes can be expressed to different degrees. The expression of 
genes is regulated by both intrinsic and external factors and gives us our phenotype. 
Microarrays offer an efficient analysis of the expression levels of thousands of genes at the 
same time, called global expression profiling. The main benefit of this technique is that the 
researcher can have an unbiased approach and does not need to take prior decision on which 
genes should be examined. The microarray results also provide information on the magnitude 
of the expression levels. The technique is robust and reproducible and has fast turnaround 
times. The output from two microarrays (i.e. exposed and non-exposed) can be compared and 
generate a lists of differentially expressed genes. To identify the relevant biological processes 
(pathways) that the genes are involved in Gene Set Enrichment Analysis (GSEA) is 
performed. Gene sets that are involved in specific pathways have been categorised in 
databases. GSEA identifies enriched pathways in the analysed gene set. In this study RNA 
extraction, microarray and GSEA (using The Molecular Signatures Database Hallmark Gene 
Set Collection (183)) were performed at the core facility for Bioinformatics and Expression 
Analysis at Karolinska Institute.  
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Two batches of biopsies were analysed with microarray at two different time points (2015 
and 2016). The biopsies were divided randomly into the batches. Only patients with all four 
biopsies with RNA quality and quantity above predetermined thresholds (RIN >4.8 and ≥ 100 
ng) were finally analysed. After exclusion only ten patients remained (Figure 7). A batch 
effect control was made for about 30 000 transcripts in all qualified samples. A small batch 
effect was seen between the years but, more importantly, not between pre- and post-operative 
or irradiated and non-irradiated samples meaning that batch effects are less likely to be 
confounded with the outcomes of interest. The results from the microarray were analysed in 
two ways: 1. to determine the effect of irradiation on breast adipose tissue, and 2. the effect of 
AFT on irradiated breast adipose tissue. In the first analysis, gene expression was compared 
in the irradiated and non-irradiated pre-operative biopsies, and the fold change (FC) 
calculated. The 3000 most dysregulated transcripts were selected for a GSEA analysis with 
the Hallmark software to examine pathways affected by irradiation. In the second analysis, 
the FC for the 3000 genes identified in analysis 1 was calculated for the post-operative 
biopsies and compared with the pre-operative FC using a paired t-test for each patient and 
gene to detect genes affected by irradiation and subsequently affected by AFT. Significantly 
altered genes (high or low pre-operative FC compared to post-operative FC close to 1) were 
further analysed with Hallmark software to identify pathways associated with an effect 
caused by AFT.  
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Figure 7. Flow diagram showing the number of patients whose data were included in the final 
analysis in study IV. 
 
5.4.2 Immunohistochemistry 
Immunohistochemistry (IHC) is a method used to visualise cellular components in tissue 
samples. The most common IHC method is based on antibodies that afford various structures’ 
colour, making them visible in a microscope. The technique was invented already in the 
1940s (184) and is widely used in research and as a diagnostic tool in health care. The four 
biopsies from each of the ten patients were examined with immunohistochemistry (IHC). 
Macrophages were chosen to evaluate the degree of inflammation in the tissues. CD68 
(Cluster of Differentiation 68) is a transmembrane glycoprotein that is highly expressed in 
tissue macrophages (185). The antibody is routinely used in pathology for diagnostic assays 
and there are well-established protocols for its use (186-188). CD68 antibody staining was 
performed to label macrophages. Two independent, blinded co-workers manually quantified 
stained cells (Figure 8). The ratios of cells per mm2 in pre- and post-AFT irradiated/non-
irradiated samples were compared.  
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Figure 8. CD68-stained adipose tissue. Arrows indicating stained macrophages and monocytes.       
a) Non-irradiated adipose tissue b) Irradiated adipose tissue c) Non-irradiated adipose tissue after 
AFT to the contralateral breast d) Irradiated adipose tissue after AFT 
 
 
  40 
5.5 STATISTICAL METHODS 
Study I was a descriptive cross sectional study. No statistical analysis was carried out. 
 
In the second study the numerically scored items (1-4 and 9-20) were evaluated in two ways: 
firstly, by displaying the results from all patients and time points in mean-line graphs, and 
secondly the changes in scores between baseline and 12 and 24 months follow-up were 
analysed using a Mixed effect Model Repeated Measures (MMRM). The outcome variable 
was the change from baseline and the baseline value was included as a covariate in the model. 
This model was chosen since it not only takes repeated measures into account, but also 
missing data. This method is recommended in longitudinal clinical trials rather than 
imputation or other methods of handling missing data (189). MMRM takes only the patients 
who completed the questionnaire both before AFT and two years after into account. Two sub-
analyses were carried out, one with irradiated patients and one with the patients who had not 
undergone additional ipsilateral surgery. For the ordinally scored items (5-8) an ordinal trend 
(OT) was calculated. The OT is the probability that the patient scored a category less positive 
at baseline than after two years. The items were analysed using a quasi-symmetry model to 
determine OT. This method is used to calculate trends of flows between categories, and 
provides an estimate of the probability of the flow of answers from one category to another in 
an item. 
 
In the third study, differences between the frequencies of the outcomes pre- and post-
operatively were tested using McNemar’s chi2 test. The Mann-Whitney test was used to 
investigate whether age, follow-up time, amount of fat injected or time from last operation to 
AFT differed between the patients with oil cysts, calcifications/progression of calcifications 
and regression of scarring and those without. Risk ratios were calculated with 95% 
confidence intervals. 
 
Since no comparable studies had been published when Study IV was started, it was not 
possible to carry out any statistical power calculations. A non-paired t-test was used to 
compare gene expression levels in irradiated and non-irradiated pre-operative biopsies. The 
FC was calculated in pre-operative biopsies and compared with the FC in the post-operative 
biopsies. The difference between the FC pre- and post-operatively was then tested with a 
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paired t-test (significance level 5%). Type 1 errors due to multiple testing were taken into 
account using the false discovery rate (FDR), and q-values <0.05. An FDR is the predicted 
rate of type 1 errors in a test. No statistical analysis was applied to macrophage density due to 
the small sample size. 
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6 RESULTS 
6.1 PATIENTS’ SATISFACTION WITH AFT AND REPORTED 
COMPLICATIONS  
This study is an evaluation of the first patients that underwent AFT in Karolinska University 
Hospital. Of the 44 patients invited to take part in this study, one did not answer and could 
not be located. Her characteristics, complications and volume of injected fat did not differ 
significantly from those of the other women. Twenty-seven out of the remaining 43 patients 
had undergone additional surgical procedures. The most frequent procedure was capsulotomy 
with implant replacement.  
 
Generally, the patients rated the outcome after AFT better than before, apart from sensibility 
and quality of the skin, for which the majority of patients’ scores remained unchanged. Four 
patients reported adverse effects: two of them reported worse scores for size, shape and 
irregularities, one patient reported that the size was worse and one of patients that the 
sensibility had deteriorated. Two patients suffered from pain at the donor site and four had 
discomforts at the donor site (Table 2). The discomforts were by three patients described as 
unevenness and indurations and one patient as distension. Only one minor complication was 
found in the medical records; a local infection which was treated with oral antibiotics. 
 
Table 2 Frequency tables of patients’ answers in each category 
 Much worse Worse Unchanged Better Much better 
Consistency 0 0 17 22 4 
Size 0 3 19 17 3 
Shape 0 2 13 21 5 
Sensibility 0 1 31 11 0 
Skin quality 0 0 35 7 1 
Irregularities 0 2 11 24 5 
	 	 	 	 	 	
  	
Yes No 
	Pain at the donor site 2 41 		
Other discomforts at donor site 4 38 		
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6.2 PATIENT-REPORTED OUTCOME AFTER AFT 
To be able to measure change over time, the patients were required to answer either the 
baseline questionnaire or at least two post-operative questionnaires. All questions are given in 
Table 3. Out of the 50 patients included in this study, two were excluded due to the absence 
of completed questionnaires. Thirty-eight patients completed the SSQ and 34 the SF-36, both 
prior to AFT and two years after AFT and were therefore included in the MMRM analyses 
(Figure 6). 
 
The mean line graphs (Paper 2, Figure 2) show similar patterns, with high scores after six 
months, followed by a decrease after one year, and an increase after two years. The questions 
and scores are given in Table 3 and Figure 9. In the MMRM analysis 13 of the 16 items were 
significantly improved after two years. This was also seen after one year with the exception 
of softness of the breast. Sub-analyses of the irradiated patients and patients that had not 
undergone major additional ipsilateral surgery showed similar results after two years. Three 
out of four items on an ordinal scale had a significant OT. However, the confidence intervals 
were very wide. 
 
No changes were seen in the eight domains of SF-36 over time. The study group did not 
largely differ from the reference population, before or after AFT (Paper 2, Figure 4).  
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Table 3. Questions in SSQ 
1 How is the sensation in the nipple area? 
2 How is the sensation in the breast skin? 
3 How is your ability to feel sexual sensation in the breasts? 
4 Do you have pain in the breasts/breast region? 
5 Are your breasts of great importance in your sexuality? 
6 Do you feel sexually unattractive because of your breasts?  
7 Is it hard for you to look at yourself naked because of your breasts? 
8 Is it hard for you to show yourself naked to your partner? 
9 What do you think about the size of your breasts? 
10 Are the breasts of equal size? 
11 What do you think of the shape of your breasts? 
12 Are the breasts of equal shape? 
13 What do you think about the softness of your breasts? 
14 Are you satisfied with the appearance of your breasts? 
15 What do you think about the appearance of the breast when you wear clothes? 
16 What do you think of the breast's appearance when you are wearing swimwear / a bra? 
17 What do you think of the breast's appearance when you are naked? 
18 What do you think of the scars from previous cancer surgery? 
19 Do you have trouble finding a bra that fits your breasts? 
20 Do your breasts affect your willingness to swim in public environments (swimming pool, beach, etc.) or participate in gymnastics and similar activities? 
 
 
 
Figure 9. Scores for item 1-4 and 9-20 on a 7-point scale. The questions are given in Table 3. 
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6.3 EFFECTS OF AFT ON POST-OPERATIVE RADIOLOGICAL 
ASSESSMENT 
All 44 of the breasts examined in Study III had a BI-RADS score of 2 both before and after 
AFT. Twelve had pre-operative calcifications. Among these, four had an increased number of 
calcifications post-operatively. Calcifications had developed in five breasts post-operatively. 
This increase of calcifications after AFT was not statistically significant compared to before 
AFT. None of the calcifications was clinically relevant and would not have been taken into 
consideration in clinical practice. Scaring due to previous surgery was seen in all pre-
operative mammograms. Reduced scarring was seen in 8 of the 24 post-operative 
mammograms, but the difference was not significant. Oil cysts were detected with ultrasound 
in one breast pre-operatively and in 15 post-operatively (p = 0.0013). None of the breasts 
showed any fat necrosis (Paper 3, Table 2). 
 
No differences were found in the follow-up time, volume of fat injected, age at first AFT or 
time from last operation to first AFT between: a) breasts in which new calcifications and 
progress in calcification were detected post-operatively and those without, b) breasts with and 
without reduced scarring, and c) breasts with and without post-operative oil cysts, with the 
exception that significantly larger fat volumes had been injected into breasts with oil cysts (p 
= 0.013) (Table 4). 
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Table 4. The results of the analysis in Study III to determine whether follow-up time, 
injected fat volume, age at surgery or time from last o to first AFT had any impact 
on the outcome in terms of BI-RADS score, calcifications, scarring, oil cysts or fat 
necrosis 
  BI-RADS Calcifications Scaring Oil cysts Necrosis 
Difference between pre- 
and post-operative 
examination 
No No No Yes No 
Follow-up time - No No No No 
Injected fat volume - No No Yes No 
Age at surgery  - No No No No 
Time from last surgery to 
first AFT - No No No No 
 
Six breasts had palpable lumps requiring FNAC. Moreover, the radiologist performed FNAC 
in three breasts. Oil from one of the lesions was discarded and not further investigated. 
Cytological examination showed four patients with fat necrosis, two with benign mammary 
tissue and oil, one with normal adipose tissue and one patient with a cyst.  
 
6.4 EFFECTS OF AFT ON GENE EXPRESSION IN IRRADIATED 
ADIPOSE TISSUE 
In the first analysis, to determine the effect of irradiation on breast adipose tissue, the gene 
encoding for connective tissue growth factor (CTGF) was among the most dysregulated 
genes (p=0.0003). It is also present in the EMT pathway, which was the most significantly 
altered pathway, according to the Hallmark analysis. Interferon gamma (IFNγ) response was 
the second most altered pathway among the 45 gene sets identified (p-values range from 
1.29×10-24 to 0.0231 for the 45 pathways). In the second analysis, to determine the effect of 
AFT on irradiated breast adipose tissue, 575 (19%) of the 3000 genes examined, including 
the gene for CTGF (p=0.004), showed significantly less variation between the respective 
sides (p-value range 1.02×10-4-0.0129) after AFT than before. Hallmark analysis of these 
genes revealed 13 significant pathways. The most altered pathway was IFNγ (p=1.02×10-5) 
followed by hypoxia (p=6.38×10-5). All pathways affected by AFT were also found among 
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the pathways affected by irradiation (Figure 2, Paper IV). The FDR (expected proportion of 
falsely rejected null hypotheses) was <0.05 in all analysed transcripts.  
 
The IHC slides from five of the ten patients had acceptable tissue and stain-quality for 
assessment in all four slides (irradiated and non-irradiated before AFT and irradiated and 
non-irradiated after AFT to the irradiated side). The cell density ratio (irradiated/non-
irradiated before AFT versus irradiated/non-irradiated after AFT) was decreased after AFT in 
all patients except one.
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7 DISCUSSION 
Studies on the most important aspects of autologous fat transplantation, namely oncological 
safety, radiological safety and PRO, are still sparse. Most of the studies have a low evidence 
level, but point in the same direction with favourable results. It is still not known whether 
AFT induces recurrence of breast cancer in a certain patient group, or whether AFT makes 
radiological examinations difficult, possibly leading to missed tumours. Neither do we know 
the extent to which AFT affects PRO. Moreover, the positive effects of AFT on irradiated 
tissue have still not been fully explained. These gaps and deficiencies in this research field 
have also been addressed by Agha et al. who are currently developing a “core outcome set” 
with the aim of increasing the quality of research in this particular field (190, 191). We do 
know that the method is popular among both patients and surgeons, and the complication rate 
is low, with very low morbidity. The research presented in this thesis has improved our 
knowledge on AFT as a complementary method in breast reconstruction following surgery 
and radiotherapy for breast cancer. 
 
7.1 STUDY I 
At the time of Study I, the effect of AFT on oncological safety and surgical safety was the 
subject of debate, and no studies had been published on patients’ experience of AFT, apart 
from one-question surveys. Moreover, reports on occasional adverse effects, such as giant 
lumps, sepsis and pneumothorax (130, 192-194) made it even more important to evaluate this 
method, which had recently been implemented at the clinic. It is particularly important to 
ascertain that surgery performed to increase the patient’s satisfaction, by enhancing the 
aesthetic outcome, truly benefits the patient and does not lead to harm.  
 
Study I of this thesis presented the first evaluation of a recently implemented complementary 
surgical procedure and an important first report on patients’ experience. The overall scoring 
by the patients was positive, indicating that AFT is a good method in terms of PRO for breast 
reconstruction.  Importantly, the complication rate was found to be low. The discomforts 
reported in the questionnaire were minor and did not need any intervention. As a result of this 
study, the method gained further acceptance at the clinic, and a more extensive parallel case 
series study was undertaken to assess PRO. Limitations of Study I are the lack of a control 
group (either a separate group, or a pre-operative group for comparison with the post-
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operative group), and the non-validated questionnaire. Moreover, it was a retrospective study, 
the patient was asked to compare the post-operative result with the pre-operative, which 
makes it difficult to draw any major inferences from the findings, except that the majority of 
patients were content with the result and that AFT appears to be a surgically safe method. 
 
7.2 STUDY II 
The results in the current study indicate an enhanced appearance of the breast. More 
importantly AFT appears to benefit the patients in other aspects. The patients report less 
discomfort with being seen naked, feeling of being more sexually attractive, less pain, 
improved softness of the breast and willingness to participate in public physical activities. 
Only four of the 20 items were not significantly improved, sensibility being the most 
pronounced. This indicates that PRO may be improved several years after AFT. Although the 
study sample was small, and no control group was available, the findings of this study 
contribute to the PRO knowledge base. Eleven of the 48 patients underwent additional 
ipsilateral procedures during the study period. Seven of them were planned nipple surgery to 
fulfil the breast reconstruction, which was not likely to have any effect on the items studied. 
Four patients underwent more extensive surgery, which may have affected PRO. One of them 
was not included in the MMRM analysis because of uncompleted baseline SSQ. The 
remaining three patients were excluded in a subgroup analysis with the same result as the 
complete group. 
 
Only two other studies have been published concerning PRO after AFT, both using a more 
complex instrument than a one-question survey. In a non-randomised trial (140), involving 
women who had undergone implant-based reconstruction, those receiving AFT reported 
better fitting of clothes, softness of the breast, symmetry, attractiveness and acceptance of 
their body, as well as less pain, than the controls (not undergoing AFT). This is in line with 
the findings of the current study. However, these authors only measured PRO post-
operatively, which makes it impossible to know whether the outcome was due to AFT or the 
implant. In the other study, a large case-control study (139), in which cases and controls had 
dissimilar characteristics (the controls had more favourable preconditions) and about 20% of 
the controls had previously undergone AFT, both groups scored similar at baseline and after 
two years, regarding satisfaction with the breast and sexual, physical and psychosocial well-
being. Unfortunately the study did not include comparison of pre- and post-operative scores. 
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Neither of these studies confirms that AFT has beneficial effects in breast reconstruction, 
however, they provide no evidence to the contrary.  
The HRQoL results of SF-36 did not change largely after AFT. Neither did the results largely 
differ from the reference population. The small sample size limits the possibility to find small 
differences between groups and overtime. SF-36 may be too blunt an instrument for 
investigating changes in HRQoL for this patient group. 
 
7.3 STUDY III 
The patients’ BI-RADS scores did not change after AFT in this study. In order to answer the 
question if AFT has any negative effects on future radiological assessment, a case-control 
study with the same approach, with pre- and post-operative radiological examinations would 
have been more appropriate. Long-term follow-up, with the assessment of yearly 
mammograms would therefore be necessary to investigate whether local recurrences have the 
same appearance in AFT-treated breasts as in non-treated breasts. No cases of fat necrosis 
were identified with radiology, but four were diagnosed with FNAC. It is possible that the 
experience of fat necrosis differs between specialists, and its evaluation is, in many ways, 
subjective. Fat necrosis is one of the most commonly reported complications of AFT and a 
common management is therefore desirable.   
 
The findings of this study showed a probable causality between large amounts of injected fat 
and the formation of oil cysts. This is important knowledge for surgeons, and valuable 
information for reducing anxiety in concerned patients. The inconsistency of the results may 
be due to variations in surgical techniques and differences in radiologists’ stringency in 
reporting findings. The main disadvantage of AFT is the necessity for the investigation of 
benign masses and radiological findings induced by AFT, which would otherwise not be 
required. 
 
7.4 STUDY IV 
To the best of the authors’ knowledge, no other studies have been performed involving global 
gene expression profiling of irradiated human breast adipose tissue. In the present study, gene 
expression was compared before and after AFT. The prospective setting, with the patients as 
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their own controls, provides the opportunity to examine biological mechanisms related to 
AFT in irradiated human tissue.  
 
CTGF is known to be correlated to fibrotic cascades caused by irradiation in vascular and 
lung tissue (51, 195, 196). CTGF has also been shown to activate EMT in mice (197). 
Moreover, EMT is known to be activated by irradiation in other tissues and contributes 
significantly to the development of RIF (42, 45, 51, 198). In the present study, CTGF was 
one of the most up-regulated genes in the irradiated pre-operative biopsy samples, and EMT 
the most affected pathway. Irradiation has been shown to cause hypovascularity and 
vasculopathy, as well as inducing hypoxia, which also plays a major role in RIF, causes 
perivascular matrix deposition, and induces extracellular matrix synthesis (47-52, 113, 161, 
164). AFT has been shown to gradually improve and normalise microcirculation with higher 
hydration and less fibrosis (113). The current findings, of highly dysregulated CTGF gene 
expression and altered EMT and Hypoxia pathways in human adipose tissue correlate with 
existing knowledge from other types of irradiated tissue, and therefore provide a relevant 
contribution to the literature. Moreover, EMT and hypoxia were two of the 13 pathways that 
were significantly reversed after AFT, which implies that AFT has a biological healing effect 
on RIF. The IFNγ response pathway is associated with inflammatory responses to ionizing 
radiation, and inflammatory cytokines play an essential role in the development of fibrosis 
(50, 199, 200). In this current study IFNγ was highly dysregulated before AFT showing that 
radiation-induced reaction is continuing years after RT. Dysregulated gene expression 
patterns for several genes in the IFNγ pathway was nearly normalised in the irradiated breast 
after AFT. An increase in macrophage influx after RT and a reduction after AFT have been 
reported previously in both humans and mice (113, 201). Moreover, the macrophage density 
was higher in irradiated tissue before AFT than after AFT. This implies that inflammatory 
responses are activated a long time after RT in adipose tissue. The effects of irradiation were 
seen up to 14 years after radiotherapy in the present study. 
 
The experiments in this study were conducted on RNA level, and therefore describe only 
gene expression and not what happens on the protein level. However, the findings correlate 
with available data and support observations in animal models. 
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7.5 LIMITATIONS OF THE STUDIES 
No obvious control group is available when assessing PRO in relation to AFT as a 
complement to BCS or breast reconstruction. A case-control study would suffer from reduced 
precision since the controls would not have any indication for AFT, and would thus be a 
different population. A cohort study would not be practical since the group of AFT patients is 
rather small, although the number is increasing. However, such a cohort would have to be 
very large. Moreover, a cohort study would suffer from the same problem with controls as in 
a case-control study. The only other possible study design would be a randomised controlled 
trial in which half of the patients with indications for AFT would not be offered this 
alternative. This would not be ethically acceptable given that the hypothesis is that AFT is 
superior to no AFT. Thus, a case-series may be the only possible option. 
 
The two study-specific questionnaires used in Studies I and II were not validated, and 
therefore constitute limitations. However, when the two studies started, no validated 
questionnaires relevant for breast reconstruction were available in Swedish, therefore the only 
choice was to develop our own questionnaires.  
 
All the studies suffer from small sample size, resulting in low statistical power. During the 
inclusion period, the number of eligible patients was small, and thus only limited numbers of 
patients could be recruited. The situation today has improved. The number of patients in 
Study IV is in the normal range for this kind of experimental gene expression study. The 
internal controls gave the study higher statistical power.  
 
A large number of variables were tested in Studies II and III. There is thus a risk of type I 
errors, false-positives, due to multiple testing, especially in Study II where most of the null 
hypotheses were rejected. In Study IV the FDR was used to make allowances for multiple 
testing and was <0.05 in all analysed pathways.  
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7.6 INTERNAL VALIDITY 
The study-specific questionnaires used in Studies I and II may be a source of systematic 
errors since they were not validated. The reliability over time should not be affected, as the 
measurements would be equally incorrect both before and after AFT. However, the accuracy 
could be affected. The Swedish reference population for SF-36 was generated in 1991-92, 
and it is possible that the HRQoL has changed since then. Comparison of the present study 
group with the Swedish reference population may therefore be less correct, but the 
comparison between time points will still be valid.  
 
7.6.1 Bias 
7.6.1.1 Selection bias 
There is thought to be little selection bias in the present studies as the patients reflect the 
patient group with indications for AFT. One could off cause speculate that challenging 
patients were not offered AFT at all. Patients not invited to participate in the studies did not 
receive any equivalent treatment, and were therefore not even eligible for inclusion. On the 
other hand, the medical assessment of whether the patient would benefit from AFT or not is 
subjective, and surgeons who suggest surgical procedures in public health care are influenced 
by the patient’s wish or willingness to undergo further surgery. At the time of inclusion, this 
was a new method for the surgeons, and the indications for AFT may have changed, 
intentionally or unintentionally, with increased experience of the surgeons. If this is the case, 
the patients in Studies I and II may perhaps not be representative of all patients undergoing 
AFT today. 
 
7.6.1.2 Information bias 
There may be a problem with recall bias in Study I since the patients were asked to assess the 
outcome compared to conditions before AFT. 
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7.6.1.3 Missing data  
A lack of completed questionnaires at different time points could induce bias. Attempts were 
made to avoid this in Study II by using MMRM. 
 
7.6.2 Confounding 
In Studies I-III, surgery other than AFT performed during the study period could be a 
confounding factor. This was avoided by excluding all patients who underwent additional 
surgery in a sub-analysis. In Study IV a batch effect could have occurred since microarray 
was carried out at two time points. Batch effect controls showed insignificant effect of the 
time-related aspect. No batch effect was found in the non-irradiated control biopsies over 
time (from before to after AFT), but differed from the irradiated breast biopsies both pre and 
post AFT. 
 
7.6.3 Effect modification 
Time from breast cancer surgery and RT could affect the patients’ answers in Studies I and II. 
Time heals, in Study II the range in time from RT was one to 22 years with a median of about 
3.5. It is possible that the patients with one and 22 years history answered differently just 
because of time. In Study IV, the time from RT to AFT could affect the outcome positively or 
negatively. The effects of irradiation may be more profound after a short period and then 
diminish over time. However, it has been seen that these effects are sustained over years in 
many patients. The gene expression in chronically radiation-damaged tissue may also change 
over time. No adjustment was made for time from RT to AFT. 
 
7.7 EXTERNAL VALIDITY  
Studies I and II were conducted in an urban setting in Sweden, a wealthy country with one of 
the world’s highest degrees of equality. It could be speculated that this may have an effect on 
how important the appearance of her breasts is to a woman. Satisfaction with, and perception 
of, body image differ between cultures (202). There is also a difference in the rate of aesthetic 
breast augmentation between Western countries. In 2016, the incidence of breast 
augmentation was about 0.03% in Sweden, whereas in France, Italy and the US the incidence 
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was two to three times higher (203, 204). This difference could reflect the prevailing societal 
attitude to the importance of the appearance of breasts. AFT and breast reconstruction are 
available through the national health service in Sweden. It is therefore possible that patients 
undergoing this form of surgery in countries where breast reconstruction is not generally 
available, or health insurance is required, may differ socioeconomically from the study 
population in this research. In Study III, radiologists assessed the increased amount of 
calcification in the breast, the amount of scarring and the reduction in scarring subjectively. 
There is thus reason to believe that radiologists may assess differently. The findings of Study 
IV could probably be generalised to other populations. There is no reason to believe that 
radiation-induced changes in gene expression in other populations would diverge from that of 
Swedish women. If differences in gene expression in adipose tissue between populations 
exist, it is more likely that the effect of the injected healthy adipocytes on gene expression 
would diverge. The internal controls increase the generalizability. 
 
7.8 PRECISION 
Random errors could be present as a result of the small study groups. Furthermore, a large 
amount of data from the questionnaires and patients’ medical records were entered manually 
into spreadsheets for analysis, and some data could have been entered erroneously. In Study 
IV, random errors could have occurred during RNA preparation, microarray analysis or 
staining procedures. Experienced analysts at the core facility for Bioinformatics and 
Expression Analysis and at the Department of Clinical Pathology at Karolinska University 
Hospital performed all the laboratory work, which should have decreased the risk of such 
errors. 
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8 CONCLUSIONS 
The main conclusions from the studies on AFT for corrective surgery after breast conserving 
surgery and radiotherapy or breast reconstruction with or without previous radiotherapy, 
presented in this thesis, are given below. 
 
 A majority of women who have undergone AFT, report improvements 
postoperatively. AFT results in few and minor postoperative complications. 
 
 AFT enhances the patient-reported aesthetic outcome. The women become more 
comfortable with being seen naked, consider themself more sexually attractive and 
are more willing to participate in public physical activities. AFT may also reduce pain 
and make the breast tissue softer, alleviating the adverse effects of breast cancer 
surgery and RT. The study groups HRQoL was comparable to that of a Swedish 
reference population. 
 
 AFT does not appear to negatively affect radiological assessment of the breast when 
performed by experienced radiologists. AFT can cause oil cysts and larger volume of 
injected fat appears to increase the risk of developing oil cysts. 
 
 Irradiation appears to have a persisting effect on gene expression in breast adipose 
tissue. AFT could conceivably reverse irradiation-induced gene expression alterations 
several years after radiotherapy. Among the detected genes, biological pathways 
associated with fibrosis, inflammation and hypoxia apperes to be the most enriched.  
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9 FUTURE PERSPECTIVES 
Given that it is still uncertain to what degree the patients benefit from repeated AFT surgery 
with limited fat volumes, the aesthetic result alone may not necessarily be the main indication 
for AFT in public health care in Sweden. The indications should probably be broadened to 
include other aspects. About 15-25% of patients treated surgically for breast cancer suffer 
from long-lasting pain in the area (205). Patients suffering from pain resulting from surgery 
or the adverse effects of RT could be a future patient group. Studies have shown that AFT 
can reduce pain in the area. It has also been shown in clinical studies that chronic 
inflammation and fibrosis resulting from irradiation can be reversed with AFT, which was 
also found in this work. Moreover, performing AFT prior to breast reconstruction with 
implants after RT may increase the chances of a complication-free procedure (206), or make 
it possible to use this reconstruction method in more patients than today. 
 
Total breast reconstructions with AFT have been carried out in other countries (132, 207). 
Mastectomised women, previously treated with or without adjuvant RT, have undergone 
repeated AFT procedures to achieve the desired breast volume. An American plastic surgeon 
has invented the BRAVA device, a plastic dome that is placed over the chest to expand the 
tissue externally with continuous suction before breast reconstruction with AFT (115). Total 
breast reconstruction with AFT may be one method of the future to reconstruct autologous 
breasts with minimal surgery, at least for smaller breasts. Larger volumes of injected fat 
could also be used to achieve symmetry as an alternative or complement to contralateral 
breast reduction. 
 
Sweden has a well-established system of registries, for example, national quality registries, 
cancer registries and the Swedish cause of death registry. Most of these registries are of high 
quality and have a high coverage rate. A registry-based case-control study in collaboration 
with the Clinical Epidemiology Core Facility at the Karolinska Institute would increase our 
knowledge on oncological safety. All breast cancer patients who have undergone AFT at 
Karolinska University Hospital, and, if possible, also at other university hospitals in Sweden, 
could be matched with breast cancer patients who have not undergone AFT by age, breast 
cancer stage, treatment and time since the completion of treatment. The outcomes studied 
could be progression-free survival and death from breast cancer. 
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It would also be interesting to conduct a randomised controlled trial in collaboration with 
specialists in pain medicine, including patients who suffer from pain in the area of previous 
breast surgery or breast reconstruction. The patients would be allocated either to continuing 
their current treatment/strategy or to receiving best-known medical treatment or AFT. A 
similar study has been carried out in Denmark with good results, showing decreased pain 
after AFT but these findings remain to be confirmed (101).
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11 SAMMANFATTNING PÅ SVENSKA 
Autolog fettransplantation (AFT) är en metod för att förbättra ett brösts utseende efter 
bröstcancerkirurgi, strålbehandling eller bröstrekonstruktion. AFT kan bland annat användas 
för att jämna ut oregelbundenheter, justera volymsunderskott och mjuka upp hård ärrvävnad. 
Fett skördas genom fettsugning på till exempel buken. Det prepareras och injiceras sedan i 
fina kanaler i det område som ska behandlas. I Sverige är idag huvudsyftet med AFT 
förbättring av patientens livskvalitet, men trots detta är forskningen om patienters 
erfarenheter av metoden begränsad. Vidare råder det osäkerhet om huruvida AFT försvårar 
bedömningen av radiologiska undersökningar. På 1980-talet skrev The American Society of 
Plastic Surgeons att användandet av AFT skulle kunna dölja cancer samt leda till falskt 
positiva radiologiska fynd och onödiga undersökningar. Idag avråder de inte från metoden på 
grund av bristande underlag men uppmanar till ytterligare studier i ämnet. Utöver estetisk 
förbättring, kan AFT användas för att behandla strålskador som uppstår i hud och 
underliggande vävnader efter strålbehandling och som kan kvarstå i många år. Effekten av 
AFT på strålskador, så som kronisk inflammation och fibros, är väl beskriven i kliniska 
studier men de biologiska processerna är fortfarande okända. Målet för detta arbete var att 
med bakgrund av ovanstående undersöka patientrapporterat utfall, radiologi samt genuttryck i 
fett efter AFT. Avhandlingen består av fyra studier med syfte att öka kunskapen om 
patientrapporterat utfall, radiologi samt genexpression i strålad bröstvävnad före och efter 
AFT. 
 
Den första studien genomfördes för att utvärdera en för kliniken då ny metod. Syftet var att 
undersöka de första patienternas erfarenhet och identifiera eventuella komplikationer. Syftet 
med den andra studien var att undersöka patientrapporterat utfall genom att jämföra pre- och 
postoperativa självskattningsformulär samt bedöma patienternas livskvalitet. I den tredje 
studien var syftet att studera vilka effekter AFT haft på den radiologiska bedömningen av 
mammografi och ultraljud. Syftet med den fjärde studien var att undersöka huruvida 
genuttryck i bröstfettvävnad förändras efter strålbehandling och vidare om AFT i sin tur 
förändrar genuttryck i den strålade bröstvävnaden. 
 
Studie I är en retrospektiv studie som utvärderar 43 patienters upplevelse av AFT med ett 
studiespecifikt frågeformulär efter operationen. Komplikationer från 44 patienter 
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registrerades. En majoritet av patienterna rapporterade förbättringar eter AFT. En patient 
hade fått en lokal infektion, vilken behandlades med peroral antibiotika. 
 
Studie II är en prospektiv fallserie i vilken patientrapporterat utfall undersöktes bland 48 
patienter med ett studiespecifikt frågeformulär och 36-item Short Form Health Survey (SF-
36), ett skattningsformulär för hälsorelaterad livskvalitet, före och två år efter AFT. I sexton 
av 20 frågor svarade patienterna mer positivt efter två år. Förbättring hade skett bland annat 
av bröststorlek, bröstform, utseende på bröstet, mjukhet, ärr, smärta, vilja att visa sig naken 
för partner och se sig själv naken, känsla av att känna sig sexuellt oattraktiv, möjlighet att 
hitta passande BH samt vilja delta i fysiska aktiviteter i offentliga miljöer. Ingen skillnad 
kunde ses i skattningen av känsel i bröstet. Resultatet för hälsorelaterad livskvalitet ändrades 
inte efter AFT. Patienternas skattning låg även i samma nivå som en referenspopulation av 
svenska kvinnor. 
 
Studie III utvärderar resultat av mammografi och ultraljud hos 44 patienter före och ett år 
efter AFT. Det visades ingen skillnad i den övergripande bedömningen, samtliga patienter 
hade BI-RADS4 score 2 (godartat utseende) både före och efter AFT. AFT ökade inte 
signifikant mängden förkalkningar eller fettnekroser men minskade inte heller ärrvävnaden. 
Antalet bröst med oljecystor ökade signifikant och det sågs också att bröst med oljecystor 
hade fått större volymer fett injicerat. 
 
Studie IV studerar genuttryck i bröstfettvävnad. Fettbiopsier togs från tio kvinnors 
strålbehandlade bröst samt det andra icke-strålbehandlade bröstet före AFT. Detta upprepades 
ett år efter att endast det strålade bröstet behandlats med AFT. Genuttrycket (de gener i DNAt 
som transkriberas till RNA och som oftast har proteiner som slutprodukt) undersöktes med 
hjälp av microarray för kvantifiering samt Hallmark gene set enrichment analysis som är en 
mjukvara för identifiering av de signaleringsvägar (biologiska processer) som de undersökta 
generna ingår i. Bland de 3000 gener med mest förändrat uttryck i en jämförelse av strålad 
och icke-strålad fettvävnad, fann man fyrtiofem signaleringsvägar som var påverkade av 
strålning. Efter AFT, i jämförelsen av strålad och AFT-behandlad fettvävnad med icke-
strålad fettvävnad, var 19 % (575) av de 3000 generna inte längre signifikant förändrade och 
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således påverkade av AFT-behandlingen. Bland de 575 generna identifierades 13 
signaleringsvägar som alla även återfinns bland de 45 initiala. De viktigaste 
signaleringsvägarna var de för interferon gamma respons som reglerar 
inflammationsreaktioner, hypoxi (syrebrist) vilket uppstår vid strålning och bidrar till de 
skadliga effekterna av denna samt epitelial mesenkymal transition som är en viktig 
komponent vid fibrosbildning vilket i sin tur leder till hypoxi. Med hjälp av immunhistokemi 
sågs ett ökat antal makrofager i strålad vävnad. Detta kunde inte ses efter AFT. Ett signifikant 
samband kunde dock ej styrkas.  
 
Slutsatserna är att autolog fettransplantation är en metod som tolereras väl av patienterna, 
vilka upplever förbättring i flera avseenden utöver förbättrad estetik. Metoden försvårar inte 
den radiologiska bedömningen men ökar antal oljecystor vid injektion med större volymer. 
Strålbehandling ändrar uttrycket i bröstfettvävnad för gener som är involverade i 
signaleringsvägar för inflammation, hypoxi och fibros. AFT verkar kunna motverka 
dysregleringen av dessa signaleringsvägar. 
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Improved shape and consistency after lipoﬁlling of the breast: Patients’
evaluation of the outcome
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Abstract
Autologous transplantation of fat, or lipoﬁlling, of the breast can correct deformities after reconstruction and after conservation
surgery for cancer. We have made a retrospective evaluation of morbidity and patients’ experiences of the method. Forty-
four patients have had lipoﬁlling once, twice, or three times (mean transplanted volume 40 ml, range 6–200 ml). One minor
complication, a local infection, was treated with antibiotics given orally, and recorded at follow up. A questionnaire was sent to
all 44 patients and answered by 43. Twenty-nine of the 43 patients reported improvement of irregularities after lipoﬁlling,
26 reported that the shape of the breast had improved, 26 that the consistency had improved, and 20 that the size had increased
postoperatively. Five of the patients reported some adverse effects; one case of liponecrosis that did not need any treatment was
found one year postoperatively. No problems were reported at the donor site at follow-up.
Key Words: Lipoﬁlling, autologous fat transplantation, fat grafting, lipomodeling, breast, breast reconstruction, breast
conservation surgery
Introduction
Transplantation of autologous fat to the breast dates
back to 1895 [1] and has been increasingly used for
various purposes by plastic surgeons for the last
25 years. The use of lipoﬁlling for mammary defor-
mities has been delayed by the possible risk of the
development of microcalciﬁcations and cysts that
might mimic malignancies or delay the diagnosis
of breast cancer. Palpable masses as a result of fat
necrosis may also be a diagnostic problem [2]. The
results after fat grafting have also been considered
unpredictable because of partial reabsorption of the
graft [3]. More recent papers have indicated that
these problems might be of less importance than
formerly believed. Good results and patients’ satis-
faction have been reported by several authors after
correction of contour deformities in reconstructed
breasts [3-9], correction of deformities after breast
conservation for breast cancer [6,10], for congenital
breast deformities such as Poland syndrome, for
tuberous breasts [3,8,9,11], and for breast augmen-
tation [3,4,8]. Many patients have postoperative
radiotherapy for breast cancer as it considerably
reduces the risk of local recurrence, but this treat-
ment increases the risk of complications and gives a
less successful aesthetic outcome after breast sur-
gery. Lipoﬁlling of breast reconstructions after irra-
diation improves the aesthetic outcome and
decreases skin atrophy, oedema, and ﬁbrosis [12].
The useful effects on the quality of tissue have been
attributed to the regenerative property of autologous
fat that contains adipose tissue-derived stem cells
(ADSC) [5,13].
We have found no other studies that speciﬁcally
addressed the patients’ experience of the method.
Here we describe our initial experiences from 43
patients with deformities after operations for breast
cancer and radiotherapy. The patients’ experiences
have been evaluated using a questionnaire.
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Patients and methods
From June 2006 to March 2010 44 patients had
lipoﬁlling after mastectomy and breast reconstruction
or breast conserving surgery for cancer in our depart-
ment. Forty-three of the patients answered a ques-
tionnaire and their results have been evaluated. We
retrospectively reviewed all the charts for the 43
patients. The patient who did not answer the ques-
tionnaire did not differ from those who answered
regarding patient characteristics, previous history,
or amount of injected fat. No complications were
recorded in her chart.
Patients
Their mean age was 53 years (range 30–72) and the
mean BMI 24.1 (range 18.5–40). Thirty-four of the
patients had hadmastectomies and 9 breast-conserving
operations. Six of those who had had mastectomy were
BRCA-1 or BRCA-2 gene mutation carriers who had
had prophylactic mastectomy. Types of breast recon-
struction are shown in Table I. Twenty-nine of
43 patients had had postoperative radiotherapy. The
median time from the end of radiotherapy to the ﬁrst
lipoﬁlling was 43 months (range 17->240). There were
four smokers in the group and none of the patients had
diabetes mellitus. According to the ASA classiﬁcation
30 were ASA 1, 11 ASA 2, and one ASA 3.
Operative technique
The areas in the breast to be treated were marked
preoperatively, with the patient standing up. Opera-
tions were done under general anaesthesia. Fat was
harvested from the abdomen using a dry technique
with a blunt Coleman cannula mounted on a 10 ml
syringe. After harvest the fat tissue was centrifuged at
3000 rpm for 3 minutes. After the liquid fat had been
disposed of, together with blood, the remaining fat was
injected into the subcutaneous tissues of the breast and
in some cases into the pectoral muscle using another
blunt cannula with a diameter of 1.29 mm. Care was
taken to inject the fat in as many thin layers as possible.
Lipoﬁlling was combined with other surgical tech-
niques in 27 of the 43 patients. (Table II).
Six of the patients had lipoﬁlling in both breasts, the
remaining 37 patients in one. Lipoﬁlling was required
once by 22 patients, twice by 18, and three times by
3 patients. The median amount of transplanted fat per
session was 40 ml (range 6–200 ml).
Questionnaire
A study-speciﬁc questionnaire was designed by the
authors and sent by mail to 44 patients at two different
times, in March 2009 and June 2010. Questions were
asked about the consistency of the breast, the size of
the breast, the shape of the breast, the sensitivity of the
skin, its quality, and irregularities of the breast.
Patients were asked to evaluate the result as either
much improved, improved, unaltered, worse, or
much worse. They were asked to report any problems
with the donor area, and also about late complica-
tions, and space was left for the patient’s own com-
ments. A reminder was sent after 1–2 months. Only
patients with a follow-up time of 6 months or longer
were included, to make sure that a consistent result
was established after initial reabsorption of fat.
Results
All patients had been seen at least once postopera-
tively at our outpatient clinic. Review of the patient
charts showed only one postoperative complication
that could be related to the lipoﬁlling. It was a local
infection/liponecrosis that had been treated with anti-
biotics given orally. No haematomas or fat necroses
necessitating reoperations or any other treatments
were recorded. There were no new lumps or other
clinical problems that needed radiological evaluation
during follow-up.
Thirty of the patients had visited their oncologist
after the lipoﬁlling, and all but one had normal ﬁnd-
ings on clinical examination. Sixteen of the patients
had had routine ultrasonography of their breasts that
showed no abnormal ﬁndings. One of the patients
developed a lump one year after the operation, but at
Table I. Breast reconstructions before lipoﬁlling in 34 patients.
Type of reconstruction
No. of
patients
No. of patients
irradiated
Expander prosthesis 21 12
Permanent prosthesis 8 4
Latissimus dorsi ﬂap and
prosthesis or expander
5 5
Table II. Simultaneous operations in 27 of 43 patients (some had
several operations).
Operations No. of patients
Capsulotomy and replacement of implant 15
Correction/reconstruction of nipple 6
Excision of skin and correction of scar 6
Liposuction in the breast 3
Abdominal advancement 3
Replacement of implant 2
Correction of ﬂap 1
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ultrasonography and mammography it was diagnosed
as typical liponecrosis, which required no additional
examinations.
The questionnaire was answered by 43 of the
44 patients, 29 of whom reported that their irregular-
ities had been improved by lipoﬁlling; 26 reported
improved shape, and 26 improved consistency.
Increased size postoperatively was found by 20 patients;
11 had improved sensitivity of the skin and 8 improved
skin quality (Figure 1). The answers from 9 patients
who had lipoﬁlling after breast conservation surgery,
were studied separately. The median amount of trans-
planted fat per session was 46.5 ml (range 15–86) and
the total injected median amount 124 (20–147) ml.
These patients were more satisﬁed with the results
of lipoﬁlling than the breast reconstruction group
(Table III).
Five patients reported adverse effects, and evalu-
ation of these is difﬁcult as they all had other
simultaneous procedures. Three patients reported
deterioration of size: two had had 17 ml and the
third 55 ml. Two of them had had liposuction in
other parts of the breast during the same operation to
improve its shape. The same patients described
deterioration of shape and irregularities. One patient
found that the size was the same or a little smaller
after lipoﬁlling with 6 ml, abdominal advancement,
and a change of prostheses. One patient found the
shape much improved after injection of 67 ml of fat,
but the sensitivity had deteriorated (Figure 1). None
of the patients had any problems from the donor site
at the time of the follow-up.
Four patients commented that the initial result of
the lipoﬁlling was good but that the effect gradually
disappeared.
It was not possible in this limited group of patients to
ﬁnd out whether there was a difference in success rate
in patients who have had radiotherapy and those who
have not, nor was it possible to correlate results with
the amount of fat that had been transplanted. It was
also not possible to distinguish the effect of the lipo-
ﬁlling itself from the effect of simultaneous operations.
Discussion
Many authors have described good cosmetic results
after lipoﬁlling [3,4,6,8,10], which agrees with our
experience. Despite the small fat volumes used in
our patients most of them were satisﬁed. The most
common good effect reported by the patients them-
selves was improved shape, including improvement in
irregularities of the breast and consistency. The
improved consistency might, at least in part, be attrib-
uted to the fact that 29 of 43 patients have undergone
radiotherapy. It has previously been shown that
radiotherapy-induced tissue damage can improve after
lipoﬁlling [5,13]. The regenerative property of the
injected fat is thought to be mediated by stem cells
derived from adipose tissue that promote neovascular-
isation of ischaemic tissues [13,14]. Improved shape
and reduced irregularities of the breast were also
reported by most of our patients, which were the
primary indications for lipoﬁlling in most of them.
Injection of relatively small fat transplants can correct
contour deformities that are important for cosmesis,
particularly in the upper medial part of the breast.
(Figures 2–4).
In 2007 Missana et al. reported results after lipo-
ﬁlling in a group of 69 patients including 9 who had
had breast conservation after breast cancer. Results
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Figure 1. Patients’ evaluation by questionnaire of the outcome after lipoﬁlling.
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were considered promising and, in their opinion,
lipoﬁlling is a good compromise between no operation
and major reconstruction [6]. Similar experiences
have been reported by Delay et al. who did lipoﬁlling
in 42 patients after breast conservation after cancer
[10]. In the present study defects after breast conser-
vation were treated in 9 patients. This group of
patients expressed greater satisfaction with the results
than did the patients who had lipoﬁlling after breast
reconstruction. This ﬁnding might reﬂect that the
reconstructed patients’ answers reﬂected satisfaction
with the breast reconstruction as well as the lipoﬁlling,
making results in the two different patient groups
difﬁcult to compare.
Postoperative reabsorption of injected fat is a well-
known problem after lipoﬁlling [1,15]. Some authors
recommend overcorrection [16] while others prefer
several sessions of lipoﬁlling [3]. Delay et al. have a
vast experience of fat transplantation to the breast and
consider that 30%-40% of the injected fat is reab-
sorbed and so overcorrect if possible [9]. Four of our
patients speciﬁcally commented on the deterioration
of the initial result. It is probable that greater volumes
or several sessions, or both, would have produced
more evident results.
We found only one postoperative complication
during follow-up that could be related to the lipo-
ﬁlling, but one patient later developed a small palpa-
ble lump in the same area where she had had
lipoﬁlling.Aftermammography andultrasonography
it was considered typical liponecrosis that did not
require treatment or further examination. These
Table III. Patients’ evaluation of results.
After breast conservation (n = 9) After breast reconstruction (n = 34)
Better Unchanged Worse Better Unchanged Worse
Consistency 6 3 20 14
Size* 7 2 13 17 3
Shape** 7 2 19 11 2
Sensitivity 2 6 1 9 25
Quality of skin 4 5 4 30
Irregularities* 7 2 22 9 2
*One additional patient answered “unchanged-worse”. **One additional patient answered “unchanged-worse” and one did not answer.
Figure 2. Before (top) and after (below) one session of lipoﬁlling
with fat 34 ml 5 years after breast conservation for cancer and
radiotherapy.
Figure 3. Before (top) and after (below) 2 sessions of lipoﬁlling
(total 102 ml) to the right breast. The patient has had her breast
conserved and radiotherapy of the right breast, followed by bilateral
mastectomy. The right breast was reconstructed using a latissimus
dorsi ﬂap and a prosthesis 16 months before the ﬁrst lipoﬁlling.
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ﬁndings are similar to others. Spear et al. reported
four complications in 47 treated breasts with a mean
follow-up of 49 weeks, one cellulitis, and 3 small
liponecrotic cysts [4], Missana et al. reported ﬁve
cases of liponecrotic cysts but no early complications
after 74 procedures with 11.7 months follow-up [6],
and Rietjens et al. 7 minor complications in 194 fat
grafting procedures [17]. Rietjens et al. evaluated
mammograms in 77 patients having had breast con-
serving cancer surgery and lipoﬁlling. Four of these
patients had postoperative changes after lipoﬁlling,
all classiﬁed as benign that did not need further
investigations. The liponecroses and other mammo-
graphic ﬁndings developed gradually and it is impor-
tant that the radiologist should be informed about
lipoﬁlling. Risk of delaying breast cancer detection
was the reason for the 1987 statement of theAmerican
Society of Plastic and Reconstructive Surgeons
deploring the use of autologous fat transfer to the
breast [2]. Since then several reports have described
changes seen at mammography, ultrasonography,
andMRI after lipoﬁlling [3,17–20].Their conclusion
is that radiological changes seen after lipoﬁlling can
be differed from malignant ﬁndings by an experi-
enced radiologist.
We consider lipoﬁlling to be a good method for
improving results after breast reconstructions and
after breast conservation for breast cancer but long-
term effects of changes caused by injection of fat into
the breast remain to be studied.
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Background  
Autologous fat transplantation (AFT) is being increasingly used to improve the results after 
breast-conserving surgery and breast reconstruction. However, studies on patient-reported 
outcome (PROs) and health-related quality of life (HRQoL) after AFT are scarce. The aim of 
this prospective longitudinal case-series study was to assess PRO in women who had 
undergone AFT after surgery for breast cancer or risk-reducing mastectomy. 
  
Methods 
Fifty women, who had undergone breast-conserving surgery or breast reconstruction, needing 
corrective surgery, were consecutively included between 2008 and 2013. A 20-item study-
specific questionnaire (SSQ) and the Short Form Health Survey (SF-36) were used pre-
operatively and six months, one year and two years post-operatively, to evaluate PRO and 
HRQoL. 
 
Results 
The patients underwent three (1-4) AFT procedures, with the injection of 164 (median) 
(range 40-516) ml fat. Thirty-eight and 34 patients completed the study-specific questionnaire 
and the SF-36 respectively, both pre-operatively and after two years. Sixteen of the 20 items 
in the SSQ were improved after two years, including breast size (p<0.0001), shape 
(p<0.0001), appearance (p<0.0001), softness of the breast (p=0.001), pain in the region 
(p=0.005), scarring from previous breast surgery (p<0.001) and willingness to participate in 
public physical activities (p<0.001). HRQoL did not largely differ before and after AFT, or 
between the study group and a reference population. 
 
Conclusions 
AFT alone or in combination with other corrective surgical procedures, improved PRO after 
breast-conserving surgery and breast reconstruction in both irradiated and non-irradiated 
women. 
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Introduction 
Breast reconstruction in connection with, or after, breast cancer surgery is well known to 
improve quality of life[1-3]. The surgical methods employed range from an oncoplastic 
approach in breast cancer surgery to extensive free-flap reconstructions. All have in common 
the possible need for surgical correction due to complications or less favourable aesthetic 
outcome. Patients who have received radiotherapy of the breast or the chest wall have a 
higher frequency of complications and reoperation[4]. Common indications for reoperation 
due to unfavourable aesthetic results are indurations, scar contractures, tissue deficit and 
breast asymmetry. Autologous fat transplantation (AFT) has become a well-established 
technique for improving these conditions[5]. Clinical results and surgeon’s opinions about the 
outcome after AFT are generally reported as good[6-9]. The results of some studies indicate 
that surgeon-reported outcome and patient-reported outcome may diverge after breast 
reconstruction[10-13]. The results of these evaluations can be valuable for patients facing 
quality-of-life-improving surgery in their decision-making process. There is also an 
increasing interest in patient reported outcome measures (PROMs) for the evaluation of the 
efficacy of the health care[14-16].  
 
In most studies on patients’ opinions of the outcome of reconstructive surgery only a single 
question has been asked [8, 9, 11, 17]. We have previously reported patients’ satisfaction 
after AFT in a questionnaire-based, descriptive cross-sectional study[18]. The aim of the 
present study was to assess patient reported outcome after AFT, prospectively and 
longitudinally, as part of reconstructive breast surgery. We also wanted to assess the patients’ 
health-related quality of life (HRQoL) before and after surgery, and learn if it is consistent 
with HRQoL of a Swedish reference population. 
 
Materials and Methods 
Patients and Design 
The study design is a prospective case series including patients treated with AFT as part of 
corrective surgery at the Department of Reconstructive Plastic Surgery at Karolinska 
University Hospital in Stockholm, Sweden. The patients were consecutively enrolled from 
October 2008 until June 2013. All procedures were performed under the national health 
service. Those included were women who had undergone breast-conserving surgery with less 
favourable aesthetic results, and women who had undergone mastectomy and subsequent 
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breast reconstruction, needing corrective surgery. The inclusion criteria were: time after 
previous breast surgery or radiotherapy longer than one year, and mammography and 
ultrasound examinations performed a maximum of three months prior to AFT, to exclude any 
local recurrences. Exclusion criteria were: known breast cancer recurrence, contraindications 
for anaesthesia or surgery due to comorbidities, other serious systemic diseases that may 
affect the outcome of the procedure, and inability to understand verbal and written 
information about the study. The patients’ characteristics are given in Table 1. The study was 
approved by the Regional Ethics Review Board in Stockholm (2008/484-31/2).  
 
Autologous Fat Transplantation 
Fat aspiration was performed with a dry technique using a Coleman cannula and a 10 ml 
syringe at the donor site[19]. Donor sites were the abdomen, knees, thighs, hips, flank area, in 
one case arms, and in another the case sub-axillary region. The fat was centrifuged at 3000 
rpm for three minutes. Liquid fat and blood were poured off, and the remaining lipocytes 
were injected into the subcutaneous tissues at the recipient site in multiple layers and 
directions using a blunt cannula, 1.29 mm in diameter. Patients with implants received one 
dose of prophylactic antibiotics (cloxacillin provided they were not allergic, otherwise 
clindamycin). The patients underwent a median of three (1-4) AFT procedures unilaterally or 
bilaterally until satisfactory results were obtained. Other corrective procedures were 
performed concurrently in eleven patients: seven scheduled nipple reconstructions, one 
mastopexy, two scar corrections and one capsolutomy with implant change, abdominal 
advancement and liposuction of the axilla. The median time from the first AFT to last AFT 
was 12.3 months (range 4.2-27.5). All operations were performed under general anaesthesia 
and carried out by one of the authors.  
 
Questionnaires and Data Collection 
Demographic data were collected from electronic patient medical files that cover the whole 
catchment area. Hence, additional operations performed outside the unit and any 
complications treated at other hospitals would come to our knowledge. A study-specific 
questionnaire (SSQ) modified for this specific study population, was used. The original 
questionnaire that SSQ was based on was developed by a psychologist [20], specialised in 
oncological patients, in collaboration with experienced plastic surgeons. It has been 
consequently modified for different studies focusing on other breast reconstructive methods 
and their outcome[21, 22], This SSQ contains 16 items in which answers are given on a 
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seven-point Likert scale (Q1-Q4 & Q9-Q20), and four items (Q5-Q8) where the responses are 
‘Not at all’, ‘Little’, ‘Pretty much’ or ‘Much’. The BREAST-Q questionnaire was not 
available at the start of this study.  
 
The Short Form Health Survey[23] (SF-36) measures the patients’ long-term (four weeks) 
HRQoL. It covers eight domains: physical functioning, physical role functioning, bodily pain, 
general health, vitality, social functioning, emotional role functioning and mental health in 36 
items. The mean scores for each domain were transformed into a value on a 0 to 100 scale, 
where a higher number represents higher functioning. The eight domains of the SF-36 were 
used to compare the patients’ HRQoL with that of a Swedish reference population, change 
over time within the group. The outcome of the reference population is provided in the 
Swedish translation of SF-36 and based on answers from 3260 randomly picked women aged 
30-74 in seven Swedish regions during 1991-92.  
 
The questionnaires were answered at baseline (before AFT) and six months, one year and two 
years after the final AFT, either by mail or at the outpatient clinic. Median follow-up (time 
from final AFT procedure to last completed questionnaire) was 24.2 months (range 11.8-
32.3). The completed questionnaires were handled by the first author and not by the surgeon 
who performed the operations. 
 
Statistical Methods 
The items on an interval scale in the SSQ (Q1-Q4 & Q9-Q20) were visualized using 
descriptive statistics and mean line graphs were plotted using the results from all SSQs from 
all patients (n=48), to give an overview of the change over time for each question. The items 
were also analysed using a statistical model, Mixed-effect model repeated measures 
(MMRM), to assess the longitudinal data. This model incorporates the dependence of the 
measurements within a patient and allows missing data (i.e. SSQ not completed at six months 
and/or one year) to analyse only the answers from the patients who completed both the 
baseline and the two-year SSQ (n=38). The model generates an estimate of the mean change. 
The outcome variable was the change relative to the baseline, and the baseline value was 
included as a covariate in the model. Sensitivity analysis was performed for irradiated and 
non-irradiated patients. This was carried out to examine if AFT especially benefits the 
irradiated patients. It is not inconceivable since AFT is known to have a positive impact on 
irradiation-damaged tissue[24]. Moreover, sensitivity analysis was performed for patients 
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(92%) that had not undergone major additional surgery. The limit for the confidence interval 
was 95 % for the difference between each time point and the baseline. 
 
In the ordinal items (Q5-Q8), a quasi-symmetry model[25] was used to estimate the 
probability that a patient would score higher after two years than before surgery. Since the 
responses were given on an ordinal scale, they cannot be treated as continuous variables in 
the analyses. The model acknowledges the ordinal scale and tests for an ordinal trend.  
 
The level of significance was set to 5 % (p≤0.05) in all tests. The statistical analyses were 
performed using SAS® (Version 9.4, SAS Institute Inc., Cary, NC, USA). No imputations 
were performed and no last observation carried forward was used. 
 
No statistical calculations were performed since the number of patients only allow for 
detection of 10-20 point differences both over time within the group and between the patients 
and the reference population. Mean scores for the general Swedish population are given by 
sex and age categories in the Swedish translation of SF-36. The scores for women in the nine 
age categories between 30 and 74 years were used to calculate a mean score for all the 
women aged 30-74 (n=3260). The means were weighted with respect of number of patients in 
each age category. In that way the reference population and patients are matched on sex and 
age. Confidence interval for the computed mean for the reference population was not 
calculated.    
 
 
Results 
Patients 
Fifty patients were recruited to the study. One patient died and one dropped out before 
completing any questionnaires. Among the remaining 48 patients, eight dropped out during 
the study period, but their completed questionnaires were analysed. One dropped out because 
of breast cancer recurrence, one underwent bilateral breast augmentation at a private clinic, 
one bilateral risk-reducing mastectomy, and five patients dropped out for other reasons 
(Figure 1). Two other patients had breast cancer recurrence, but they did not drop out of the 
study.Adverse events occurred in six patients: one patient had a wound rupture, one a 
haematoma at the donor site, and four patients needed further investigations; three because of 
palpable lumps and one because of discomfort and swelling of the breast. Thirty-eight 
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patients completed the SSQ and 34 patients completed the SF-36 both at baseline and after 
two years. 
The total median volume of injected fat was 164 ml (40-516). 
 
Study-Specific Questionnaire  
Q1-Q4 and Q9-Q20 
From the mean line graphs it can be seen that the best results were obtained after six months, 
followed by a decrease after one year, and then an increase after two years (Figure 2). 
Fourteen of these 16 items (Q1, Q4 & Q9-Q20) were improved after two years. The mean 
score and mean change between baseline and two years are given for each item in Table 2 
and Figure 2. 
 
In the MMRM analysis, including only patients who completed both baseline and the two-
year questionnaire, thirteen of the 16 items were significantly improved after two years, for 
the entire group and in the sensitivity analyses for the irradiated patients and the patients who 
had not undergone additional surgery. (Q4 & Q9-Q20). Q13 (softness of the breast) was not 
significantly improved after one year (Table 3). The non-significant items (Q1-Q3) concern 
the sensitivity of the breasts. The non-irradiated subgroup was too small to make any 
inferences from the data.  
 
Q5-Q8 
The ordinal trend, i.e., the probability of more positive scores after two years, was 22.47 
(p=0.002) in Q6 (sexually unattractive because of breasts), 7.9 (p=0.003) in Q7 (seeing 
oneself naked), and 10.88 (p=0.017) in Q8 (being naked in front of partner) (Figure 3). The 
95 % CI was wide in all three items. The ordinal trend for Q5 (importance of breasts for 
sexuality) was not significant. 
 
SF-36 
The mean scores for the eight domains for the reference population were compared with the 
mean score for the study group at both baseline and after two years. No point differences 
were large enough to be able to detect any significant differences in HRQoL between the 
study group and the reference population. Neither were there any large differences between 
the mean score at baseline and at the two-year follow-up within the study group. The 
descriptive statistics are shown in Figure 4. 
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Discussion 
Patient-reported outcome measures are important tools in evidence-based medicine[26, 27]. 
The results are especially important when evaluating surgery intended to improve quality of 
life, rather than treating severe health conditions. A debate on oncological safety has been 
going on over the last three decades. It has been proposed that stem cells injected in a 
previous cancer site could induce recurrence[28]. Consequently, women offered AFT as part 
of breast reconstruction or after breast-conserving surgery should be given evidence-based 
information about the outcome of the procedure before accepting further surgery. Information 
on the outcome of different procedures is also important for health-care providers and 
funding bodies. Despite the common use of AFT, few reports have been published on the 
change of patient reported outcome over time and the quality of the reports is rather low[26]. 
When this study started, the validated BREAST-Q form was not yet available, and could 
therefore not be used as recently recommended in the VOGUE study[27]. Instead a study-
specific questionnaire was used to evaluate patient reported outcome. The patients answered 
the questionnaire before AFT, and at three time points during the two-year follow-up after 
completed AFT sessions. A research nurse handled the questionnaires. The aim was to assess 
possible changes in the patients’ opinion about the outcome over time. Resorption of the 
transplanted fat may lead to deterioration of the aesthetic result over time. On the other hand, 
as time passes, the patients may accept the cosmetic result to a larger extent and softening of 
the breast tissue[29] could lead to patients expressing a more positive opinion over time.  
 
In the present study, a more positive outcome was reported in 80 % of the items two years 
after AFT, than pre-operatively. The patients were more satisfied with the appearance of their 
breast with and without clothes, found the breast symmetry better, were more comfortable 
about being naked with their partner, and felt more sexually attractive. They were also more 
willing to participate in physical activities, and found it easier to find a good-fitting bra. The 
relatively long period between radiotherapy and AFT (median >3.5 years, extending to over 
22 years) indicates that AFT could the main reason for improved scoring post-operatively. If 
that period had been shorter, the initial negative impact of radiotherapy would decrease 
during the study period, making time the main reason why the patients have higher scores 
after two years. Eleven of the patients had other ipsilateral surgical procedures performed. 
Seven of these were elective nipple operations leaving four patients who underwent surgery 
that could have positive or negative impact on the outcome. Only three of them were included 
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in the MMRM analysis. Since these three patients had to undergo additional surgery one can 
speculate if they have scored more negatively. On the other hand the additional surgery may 
have generated even better outcome. The patients had increased in BMI from 24.7 to 25.3 
kg/m2 in median at the last follow-up. It is less likely that the small increase have an impact 
on the outcome. 
 
Various aspects of AFT have been studied, but the number of studies using PROMs is 
modest. Most publications report only a one-item evaluation, asking the patient if she is 
satisfied with the outcome, often using a 3- to 5-point Likert scale[8, 9, 17, 30]. In one study, 
200 patients were asked personally about their degree of satisfaction with the surgical 
outcome at their post-operative follow-up. All of them claimed that they were satisfied or 
very satisfied, which may imply a significant systematic bias as the evaluation was not 
anonymous[31]. In the present study, care was taken to prevent the surgeons involved from 
handling the post-operative questionnaires, so as not to influence the outcome measures. 
 
In the only multi-centre cohort study on this subject, Bennett et al.[32], reported that AFT 
patients and ‘control patients’ scored similarly at baseline regarding physical well-being, 
satisfaction with the breast, sexual well-being and psychosocial well-being. More over the 
control patients scored a little higher than the AFT patients (cases) at the one-year follow-up. 
No difference between the two groups was seen after two years. However, almost 20 % of the 
control patients had undergone AFT before baseline, which may lead to problems in the 
interpretation of the results. Moreover, no comparison was made of pre- and post-operative 
results. Nevertheless, the authors concluded that AFT provided measurable improvements in 
satisfaction, which is in line with our results. 
 
In the present study, the nine items that can be regarded as indicators of aesthetic outcome 
and symmetry were all improved. The patients’ opinion of the aesthetic outcome could 
therefore be considered improved, which was one of the main reasons for performing AFT 
(Figure 5 and 6). It is difficult to assess the impact of breast surgery on sexuality, but this is 
important for the patient’s future well-being. Many breast cancer survivors suffer from 
impaired sexuality due to a change in body image[33]. The results of this study indicate an 
improvement over time after AFT regarding feeling sexual attractive and comfortable when 
being naked. Whether this is due to AFT or the passage of time after cancer surgery and 
reconstruction is unclear. Our findings are in contrast to those in the study by Bennett et al., 
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which showed a decrease in sexual well-being over time[32]. However, we believe that the 
use of AFT as a complement to other breast surgical techniques may play a role in regaining 
a positive body image after surgery.  
 
Improvement in softness of the breast is most evident at six months and two years in the 
mean line plots (Q13). A non-significant change in softness was seen after one year, in 
contrast to two years, indicating a slightly harder breast after one year. This could be 
explained by a reduction in the initial filling effect over the first year due to resorption of the 
transplanted fat. The improvement two years post-operatively could be a biological effect in 
radiation-damaged tissue, rather than primarily the effect of the filler. AFT has been 
suggested as a treatment for radiation-induced fibrosis, as clinical findings and experimental 
studies indicate reduced fibrosis when AFT is carried out after radiation therapy[24, 34-37].  
 
The patients in the present study reported a low level of pain before AFT. Despite this, 
reduced pain in the breast region was reported at the two-year assessment. This finding, as 
well as increased breast softness, is in line with the results of a case–control study carried out 
by Panettiere et al.[38], and implies that AFT not only improves the aesthetic outcome of a 
breast reconstruction, but may also have a positive impact on morbidity after treatment for 
breast cancer. 
 
No large difference was found in HRQoL between the study group and the reference 
population, either at baseline or after two years. There is, therefore, no reason to believe that 
the patients in the study group differ from an age matched Swedish women in general when 
they decide to undergo AFT. Furthermore, it appears that AFT does not lead to a large 
decrease in HRQoL post-operatively.   
 
The strengths of this study include the prospective design, with baseline data collected pre-
operatively. However, the study has some limitations. Firstly, the study group is relatively 
small. Furthermore, additional ipsilateral surgical procedures were performed at the same 
time in a minority of the patients, and this could have influenced their opinions concerning 
the result. However, the study group represents typical patients who undergo complementary 
AFT. Another limitation is that the heterogeneity of the patient group may have effect on the 
results. A sensitivity analysis was carried out and no difference in significance was seen 
comparing results from the entire patient group with the sub-group (92% of the patients) that 
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had not undergone major additional ipsilateral surgery. No measurements of remaining fat 
volume were made post-operatively to compare with PRO. 
A validated PROM would probably have made the evidence stronger but as mentioned 
before, no such was available at the start of the study. Lastly, several hypotheses tests were 
performed hence type I errors may exist. 
 
In conclusion, the patient reported outcome improved up to two years after AFT, when the 
method was used as a complement in breast reconstruction or after breast-conserving surgery. 
Improved outcomes included better breast symmetry, size, shape and appearance. Autologous 
fat transplantation also increased the softness of the breast and reduced pain in the breast 
area. AFT did not affect HRQoL, and the study population did not differ from the reference 
population in this respect. The results of this study are of clinical importance for women 
considering AFT, to help them to make an informed decision. Nevertheless, further studies 
using PROMs after AFT and breast reconstructive surgery would be valuable to confirm our 
findings. 
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Table 1. Patient characteristics 
 
n=48, DIEP=Deep Inferior Epigastric Perforator Flap, LD=Latissimus Dorsi Flap, *Median, 
†Previous cancer surgery 
 
 
 
 
Figure 1. Flow diagram of patients’ participation in the study. Boxes on the left show the 
number of patients completing the study-specific questionnaire (SSQ) at each time point. 
Boxes in the middle show the number of patients participating in the study. Boxes on the 
right show the number of patients excluded and drop-outs. 
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.  
Figure 2. Mean line plots for Q1-Q4 and Q9-Q20. The mean line plots for each item at 
each time point are shown on the right for all patients who completed the SSQ 
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Table 2. Results for Q1-Q4 and Q9-Q20 on sensitivity, pain, appearance, softness, 
trouble finding a good-fitting bra and willingness to participate in physical activities.  
 
The questions were answered on a 7-point Likert scale. Mean score at baseline (BL) and two-
year follow-up are shown. Min=minimum change in score between baseline and 2 years. 
Max=maximum change in score between baseline and 2 years. Negative numbers indicate 
lower score at the two-year follow-up compared to baseline. SD=Standard deviation in the 
change between baseline and 2 years. 
 
 
Table 3. Q1-Q4 and Q9-Q20. 
 
Statistical analysis of questions in table 2 with MMRM for patients who completed the study-
specific questionnaire at baseline and after two years (n=38). Estimated mean change (ECh) 
from baseline to follow-up. Significant level was set on p≤0.05 with a confidence interval 
(CI) on 95%. Significant items are bold. SE=Standard error. Radiotherapy 2 years follow-
up=irradiated patients only. No additional surgery 2 years follow-up=patients that had not 
undergone major additional ipsilateral surgical procedures 
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Figure 3. Q5-Q8 focusing on sexuality and willingness to be naked. The graphs show the 
percentage of answers in each category, for each item, at baseline and after two years. The 
ordinal trend is the probability of the patient grading an item one category more positively 
after two years than at baseline. Significant items are given in boldface. CI=confidence 
interval 
 
 
 
 
Figure 4. Results for the eight domains of SF-36 of the study population and the age 
matched reference population of Swedish women (n=3260). PF=physical functioning, 
RP=physical role functioning, BP=bodily pain, GH=general health, VT= vitality, SF=social 
role functioning, RE=emotional role functioning, MH=mental health. 
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Figure 5. A 31-year-old women that presented with a scar retraction and volume deficiency 
3.6 years after breast conserving surgery and radiotherapy (left). She underwent three AFT 
procedures with totally 150 ml fat. 2.2 years post-operative the scar is not visible and the 
symmetry is better (right). 
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Figure 6. A 66-year-old woman with bilateral defects after BCS and RT (left). Time from RT 
to AFT was 2.6 years for the left breast and 1 year for the right breast. She underwent two 
AFT procedures to each breast with totally 69 ml to the left side and 100 ml to the right. In 
addition she underwent mastopexy on the right side. Post-operative images from the two-year 
follow-up are shown to the right.
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Abstract
Background Autologous fat transplantation (AFT) to the breast can correct defects and be a part of a breast
reconstruction to achieve a better aesthetic result. The impact of AFT on the radiological evaluation and detection of
cancer remains unclarified. The aim of this study is to investigate whether AFT induces lasting modifications.
Methods In the present study, a valuation was performed of 44 breasts from 37 patients examined with mam-
mography and ultrasound before and after autologous fat transplantation. Breast radiologists evaluated the images
using a study specific protocol.
Results AFT did not hinder post-operative assessment of mammograms or ultrasound. No detectable changes with
serious clinical impact were found after injections of mean 177 ml (34–516) of fat in one to four sessions. The rate of
oil cysts was significantly higher after AFT than pre-operatively (2.3 vs. 34.1 % p = 0.0013). Significantly more
post-operative oil cysts were detected after injection of larger volumes of fat (144 vs. 243 ml, p = 0.013). No
significant differences were found in the post-operative images regarding age at surgery, follow-up time, or time from
previous breast surgery.
Conclusion AFT does not impair assessment of mammograms and ultrasound in patients who have a history of
breast cancer surgery or prophylactic mastectomy.
Introduction
Autologous fat transplantation (AFT) to the breast is a
frequently used technique for the correction of breast
defects and after breast cancer surgery [1–5]. In 1987, the
American Society of Plastic and Reconstructive Surgery
(ASAP) [6] declared that breast cancer surveillance and
screening ‘‘will become difficult’’ when using autologous
fat injection to the breast. They also stated that AFT ‘‘can
inhibit early detection of breast carcinoma and is therefore
hazardous to public health.’’ Despite this, AFT has gained
in popularity and many reports have been published on
standardized techniques with good results [3, 4, 7–11]. In
2009, ASAP published a report from their Fat Graft Task
Force [12], recommending that caution be taken regarding
‘‘those with risk factors for breast cancer’’ and that there
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might be an interference with ‘‘physical examination or
breast cancer detection.’’ They concluded that AFT does
not interfere with radiological examinations in lack of
evidence of the opposite.
During recent years new studies with radiological
aspects have been published [13–21], most of these being
case reports or case series and only a few including breast
cancer patients. Regarding cancer relapse and radiological
findings, most studies do not indicate that AFT impairs
radiological evaluation but there are still doubts regarding
safety in patients with a history of cancer.
The aim of this prospective cohort study was to evaluate
radiological and ultrasound-detected changes in the breast
after AFT and to further clarify if AFT could hinder future
Table 1 Patient characteristics
n (%) SD Min Max
Patients (n = 37)
Age at first session (Mean) 54.9 8.5 39.1 71.4
Follow-up time (month) (Mean) 15.9 5.3 10.0 28.0
Patients with bilateral lipofilling 7 (18.4)
Ipsilateral surgery breasts/sessions 7 (18.4)/11 (9.2)
Capsulotomy ? implant replacement 2
Capsulotomy ? implant replacement ? scar excision 1
Liposuction 1
Liposuction ? nipple reconstruction 1
Nipple correction 1
Nipple reconstruction 2
Scar excision 3
Breasts (n = 44)
Age at first session (mean) 54.9 8.4 39.1 71.4
Follow-up time month (mean) 15.6 5.2 10.0 28.0
Time from last breast surgery to lipofilling month (mean) 47.7 34.4 10.0 152.0
Fat injected ml (mean) 177.4 116.0 34.0 516.0
Previous breast surgery
Breast conserving surgery 20 (45.5)
Mastectomy ? immediate reconstruction 12 (27.3)
Mastectomy ? delayed reconstruction 1 (2.3)
Prophylactic mastectomy ? immediate reconstruction 7 (15.9)
Mastectomy ? latissimus dorsi flap 4 (9.1)
Radiotherapy 30 (68.2)
Number of lipofilling sessions
1 4 (9.1)
2 11 (25)
3 26 (59.1)
4 3 (6.8)
Tot 116
Ultrasound pre-operatively 44 (100)
Ultrasound post-operatively 44 (100)
Mammography pre-operatively 29 (65.9)
Mammography post-operatively 26 (59.1)
FNACa 9 (20.5)
Palpable 6 (13.6)
Visible in ultrasound 3 (6.8)
Analyzed by cytologist 8 (18.2)
a FNAC fine-needle aspiration cytology
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radiological evaluations of the breast or interfere with the
detection of cancer. Our hypothesis was that AFT does not
complicate the assessment of mammograms and ultrasound
for the experienced radiologist in patients who have a
history of breast cancer surgery or prophylactic mastec-
tomy and who have undergone AFT.
Materials and methods
This is a prospective over-time cohort study comparing
mammography and ultrasound before and after AFT of the
breast.
Patients
Thirty-seven consecutive patients (44 breasts) aged
26–75 years of age were enrolled between October 2008
and May 2012. Previous breast surgery is listed in Table 1.
Exclusion criteria were \1 year since cancer surgery or
radiotherapy, systemic disease such as diabetes mellitus,
breast cancer recurrence, or less than 10 months from last
AFT to radiological examination. All patients underwent
clinical follow-up at 6, 12 and 24 months after the last
AFT. At the 12-month follow-up patients underwent
mammography and ultrasound.
Surgery
Fat was harvested by dry technique using a Coleman
cannula on a 10 ml syringe and centrifuged (3000 rpm,
3 min). The purified lipocytes were separated from liquids
and injected fan-shaped in multiple layers into the subcu-
taneous tissues using another blunt cannula (1.29 mm
diameter). All sessions were performed under general
anesthesia. One dose of intravenous antibiotics was
administered pre-operatively to patients with implants. The
patients underwent 1–4 AFT procedures until a satisfactory
result was obtained. Seven patients (11 procedures)
underwent ipsilateral surgery during one or several opera-
tions (Table 1).
Radiology
Pre-operative mammography and ultrasound was per-
formed a maximum of 3 months prior to AFT as a baseline
control. Mammograms were obtained using a Giotto
mammograph (IMS, Bologna, Italy). When possible, both
medio-lateral oblique and cranio-caudal projections were
taken. In some patients who had undergone mastectomy,
only one projection was taken. Ultrasound was performed
using an Acuson Antares Echograph (Siemens Healthcare,
Erlangen, Germany) equipped with a 5–13 MHz linear
transducer. Two experienced breast radiologists indepen-
dently assessed all the images. They made the following
evaluations compared with the pre-operative assessment:
new calcifications or a change in their quantity (together
referred to as progress in calcification), oil cysts, fat
necrosis, abnormalities or malignancies, and change in BI-
RADS (Breast Imaging Reporting and Data System) [22]
score and scarring. The BI-RADS scoring system was
adopted for the assessment of imaging findings. Individual
breast densities were not recorded as AFT did not disturb
assessment of the mammograms. When relevant, radiolo-
gists or pathologists performed fine-needle aspiration
cytology (FNAC) and a cytologist analyzed the tissue.
Ethical approval
Informed consent was obtained, and the study was
approved by the Regional Ethics Review Board in Stock-
holm (2008/484-31/2).
Statistical methods
All analyses were carried out using STATA 13.0. Distri-
butions in continuous variables were tested with the Mann–
Whitney test. Differences for categorical data were tested
using the chi-square test of independence. Risk ratios are
presented together with 95 % confidence intervals.
In the descriptive data, all breasts are included. To be
able to analyze data on an individual instead of a breast
level [i.e., to eliminate bilateral AFT as a confounder], we
excluded one breast in each patient with bilateral AFT.
Four of the patients with bilateral AFT had unilateral
cancer, and the non-cancer side was excluded. Two
patients had bilateral cancer, and we subsequently drew
Table 2 Rates of findings in mammography and ultrasound
Na %
BI-RADS 2 pre-operative 44 100
BI-RADS 2 post-operative 44 100
Calcifications pre-operative 12 41.4
Calcifications post-operative 17 65.4
Progress of calcification 8 32.0
Oil cysts pre-operative 1 2.3
Oil cysts post-operative 15b 34.1
Liponecrosis post-operative 0 0
Scarring post-operative 24 100
Better 8 33.3
Unchanged 16 66.7
a Breasts
b Difference pre and post-operatively when adjusting for bilateral
AFT p = 0.0013 McNemar’s chi-square
1106 World J Surg (2016) 40:1104–1111
123
lots. One patient had undergone a bilateral prophylactic
mastectomy, and all parameters were identical, and one of
the sides was excluded.
Results
The mean age of the patients was 54 (range 39–71) years at
follow-up. No patients were lost to follow-up. Mean time
from last breast surgery to AFT was 47.7 months (range
10–152). The mean volume of fat injected was 177.4 ml
(range 34–516). The mean follow-up time was 15.6 months
(range 10–28). All breasts were evaluated pre- and post-
operatively with ultrasound. Twenty-nine breasts had
mammograms taken pre- and 26 post-operatively. In some
patients, it was impossible to perform mammography due
to their breast reconstructions (Table 1).
Two experienced radiologists had no difficulties inter-
preting the mammograms and ultrasounds after AFT. All
patients had a BI-RADS score 2 (=benign findings) pre-
and post-operatively (Table 2). No patients had any
abnormalities or malignancies.
Fig. 1 Mammogram before
(left) and 14 months after last
(right) AFT. A 68-year-old
woman who underwent two
AFTs with a total amount of
115 ml fat injected to her left
breast. White arrows indicate
calcifications. Transparent
arrows indicate scarring. Left
medio-lateral oblique and left
cranio-caudal projections
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Twelve (41.4 %) breasts had calcifications pre- and 17
(65.4 %) post-operatively (Figs. 1, 2). Four of the 12 with
pre-operative calcifications had an increased amount of
calcifications, and, totally, 8 out of 25 (32 %) patients had
progress in calcification. All calcifications were clinically
irrelevant however, and would not have been reported by
the radiologist in clinical practice. There was no significant
difference in progress between those with and without pre-
operative calcifications (p = 0.879, RR = 1.1, 95 % CI
0.36–3.34) (Table 3). There were no differences in mean
time to follow-up, volume injected fat, age at surgery, or
time from last surgery to AFT between those with progress
in calcification at follow-up and those without progress
(Table 4). Pre-operative radiotherapy did not significantly
affect progress in calcification.
One patient had an oil cyst pre-operatively. Post-opera-
tively, 15 (34.1 %) breasts had oil cysts detected with
ultrasound (p = 0.0013) (Fig. 3). In these breasts, a
Fig. 2 Photograph and
mammogram before (left) and
13 months after last AFT
(right). A 61-year-old woman
who underwent three AFTs with
a total amount of 268 ml fat
injected to her left breast.
Arrows indicate scarring. Left
medio-lateral oblique and left
cranio-caudal projections
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significantly higher amount of fat had been injected
(p = 0.013), but there was no difference in follow-up time,
age, or time from prior surgery. No fat necrosis could be
found (Table 2).
Scarring was detected by mammography in all patients
pre-operatively (Figs. 1, 2). Twenty-four had both pre and
post-operative mammography done. Eight (33.3 %) of these
had regress of scarring after AFT with smoother breast
contours (Table 5, Fig. 2). When adjusting for bilateral
AFT, there were no differences in mean time to follow-up,
fat volume, age, or time from last surgery to AFT between
those with and without regress of scarring (Table 4).
At follow-up after AFT, six out of 44 patients had a
palpable lump that was further examined with FNAC.
Additionally, three breasts (6.8 %) had FNAC initiated by
the radiologist because of ultrasound findings. One of the
aspirations consisted of oil only and was discarded.
Histopathology showed fat necrosis in four breasts, benign
breast tissue, and oil in two breasts, one breast with normal
fat tissue and one cyst in one breast (Table 1).
Discussion
The most important issue regarding AFT is that of onco-
logical safety. This is not only a matter of possible AFT-
induced relapse or new cancers but also the possibility of
detecting malignancies. In the oncological follow-up, it is
important that the surgeon, the oncologist, and the radiol-
ogist feel familiar with the reconstruction method and the
possibility of examining a breast after AFT. Krastev et al.
recently published a systematic review [18] on the onco-
logical safety of AFT and reported, with few exceptions,
small studies, short follow-up times, and low evidence
levels. Conclusions cannot be drawn even from larger
studies [23–25] due to incomparable patient groups and
diverging results with significant overlap in the patient
groups [23, 24].
Wang [15] reported a 16.7 % frequency of ‘‘highly
suspicious’’ clustered microcalcifications after breast aug-
mentation with fat transplantation. Rietjens et al. [13]
reported 6.5 % calcifications in their control mammo-
grams. In Claro et al’s review [26], which is a mix of
studies with aesthetic and reconstructive focus with mainly
aesthetic patients, 1.6 % of the patients had microcalcifi-
cations and 8.7 % had cysts. Kim et al. [19] recently
reported a 17.6 % frequency in fat necrosis and cysts but
did not report any information on calcifications. The high
frequency of calcifications (65.4 %) in our patients com-
pared with other reports is probably due to our radiologists
Table 4 Progress in calcifications and scarring in mammography and
in oil cysts in ultrasound
Median Min Max pa
Follow-up (months)
Progress - 15.00 11.00 27.00 0.28
Progress ? 13.50 10.00 23.00
Amount of fat injected
Progress - 165.5 40.00 322.00 0.12
Progress ? 233.0 115.00 445.00
Age at session 1
Progress - 54.87 39.08 66.61 0.95
Progress ? 53.13 42.82 71.37
Time from last surgery to lipofilling
Progress - 34.00 21.00 98.00 0.37
Progress ? 45.50 20.00 120.00
Follow-up (months)
Oil cysts - 13.00 10.00 28.00 0.70
Oil cysts ? 13.00 10.00 27.00
Amount of fat injected
Oil cysts - 144.00 40.00 419.00 0.013
Oil cysts ? 243.00 74.50 516.00
Age at session 1
Oil cysts - 56.20 39.08 71.37 0.80
Oil cysts ? 49.41 44.79 67.59
Time from last surgery to lipofilling
Oil cysts - 30.00 10.00 152.00 0.36
Oil cysts ? 39.00 20.00 120.00
Follow-up (months)
Scarring better 13.00 10.00 23.00 0.17
Scarring unchanged 14.50 11.00 27.00
Amount of fat injected
Scarring better 231.00 115.00 445.00 0.39
Scarring unchanged 170.00 40.00 322.00
Age at session 1
Scarring better 57.59 46.76 67.59 0.46
Scarring unchanged 54.63 39.08 71.37
Time from last surgery to lipofilling
Scarring better 28.00 20.00 120.00 0.84
Scarring unchanged 38.50 21.00 98.00
Bold value indicates significant p-value
a Mann–Whitney test
Table 3 Rate ratio for progress of calcifications comparing with or
without pre-operative calcification
Progress of calcifications
No Yes Total
Pre-operative calcifications
No 8 4 12
Yes 7 4 11
Total 15 8 23
p = 0.8789 RR = 1.09 CI 0.36–3.34
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recording even minimal calcifications. In clinical practice,
these minimal calcifications and progresses would probably
not be mentioned in the radiological statements since they
are of no clinical interest. No significant difference in
volume between those with or without progress was found.
A tendency could be observed that the breasts with pro-
gress in calcifications had 46 % (244.2 vs.181.9) more fat
injected into them. This might imply that a larger amount
of fat generates more calcifications, a finding that is also
supported by Wang [27].
In a Japanese study [28], several patients who had pre-
viously undergone augmentation with large amounts of
autologous fat presented with large masses of fat necrosis
and oil cysts that had to be removed surgically. Even with the
injection of smaller amounts of fat, as in the present study,
AFT induced oil cysts and their presence depended on the
volume of fat injected. This emphasizes the importance of
good surgical technique especially when larger amounts of
fat are injected. It also raises the question of how large a
volume of fat is reasonable to inject at one time or if smaller
volumes in several sessions are preferable.
Recently, Agha et al. [29] published a systematic review on
autologous fat grafting, including 17 studies regarding radiol-
ogy. As in the present study, they exclusively included studies
on reconstructive breast surgery. They reported a 2.7 % fre-
quency of radiological abnormalities that had to be further
examined by biopsy. We had a higher frequency (6.8 %).
Eighty percent of the reviewed studies were case reports or
series and, therefore, hard to draw conclusions from.
Patients with regress in scarring (33 %) had had 34 %
more fat injected than those with unchanged scarring. This
difference was not significant, perhaps due to the relatively
small number of patients included. The result of fat graft-
ing can be improved in many patients by multiple sessions
of AFT, instead of overfilling in one session.
As AFT has become a common and important comple-
ment in breast reconstructions, giving the reconstructive
surgeon further possibilities to achieve a good final result,
not only radiologists at centers where the method is well
known will assess mammograms and perform ultrasound
on these women. The findings in the present study, that
evaluation of mammography and ultrasound was not
impaired, is in accordance with other studies [14] and can
facilitate the follow-up of these women also in other set-
tings than breast centers. Our study indicates that if a
patient undergoes AFT using modern techniques, there is
no risk of interference with future follow-up using mam-
mography and ultrasound.
A strength of our study is that we only included
patients with former breast cancer and those at high risk of
developing the disease, patients operated with prophylactic
surgery, and no aesthetic patients. A limitation is that
some of the patients with prosthesis could not have
mammography performed, but only ultrasound.
We did not include MRI because it is not used for the
standard evaluation of breast cancer patients in Sweden
according to the Swedish National Guidelines [30].
The patients in this study underwent treatment with
relatively small amounts of fat. Hence, the results can only
be generalized to similar patient groups. In conclusion, no
detectable serious negative effects were seen after AFT
using relatively small amounts of fat to the breast in
Fig. 3 Ultrasound image after AFT, arrows indicate oil cysts
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women with previous breast cancer surgery or prophylactic
mastectomy and reconstruction. AFT did not hinder the
assessment of mammograms or ultrasound. We found a
significantly increased number of oil cysts after injection of
larger volumes.
This study supports the safety of AFT in the aspect of
radiological follow-up of breast cancer and prophylactic
patients.
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What is already known: Clinical studies indicate that autologous fat transplantation (AFT) 
stimulates regression of chronic inflammation and fibrosis caused by radiotherapy in skin and 
subcutaneous fat. However, there is a paucity of biological evidence and the underlying 
processes are poorly understood. Human data are scarce, whereas experimental animal 
studies have mainly focused either on the effect of irradiation or AFT alone. 
 
What is new: The current study indicates that radiotherapy causes dysregulated gene 
expression in fibrosis-related pathways within adipose tissues in humans. It also shows that 
AFT causes a reversal of this with several dysregulated genes returning to nearly normal 
expression levels.  
 
Potential impact on future practice: The study provides biological evidence for AFT’s impact 
on radiation-induced dysregulated gene expression in humans. The study supports AFT to be 
indicated as treatment for radiation induced fibrosis, associated with severe morbidity and 
surgical challenges. 
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Abstract 
 
Background 
Radiation-induced fibrosis (RIF) is associated with functional and cosmetic impairment as 
well as surgical complications. Clinical reports suggest improvement following autologous 
fat transplantation (AFT), but the underlying mechanisms remain unclear. A global gene 
expression strategy was undertaken to identify how radiotherapy (RT) affected gene 
expression patterns and furthermore if AFT could affect these patterns. 
 
Method 
Adipose tissue biopsies were taken synchronously from irradiated, and contralateral non-
irradiated breasts, before and one year after AFT. The 3000 most dysregulated genes, 
comparing both breasts, were subjected to Hallmark analysis to detect enriched pathways 
among genes dysregulated by radiation. A significant enrichment of genes related to a 
specific pathway was defined as p <0.05 and false discovery rate (FDR) <0.05 was used to 
correct for type I errors. A similar comparison was conducted post-AFT to study the effect of 
AFT on gene expression patterns.  
 
Results 
Forty microarrays were analysed from biopsies taken from 10 patients pre-, and post-AFT. 
Forty-five pathways were identified among the 3000 most dysregulated transcripts pre-RT 
compared to the non-irradiated breast. Post-AFT 575 genes were altered anew and 13 
pathways identified (p<0.05; FDR<0.05). The top two canonical pathways were interferon 
gamma response and hypoxia. Correlative immunohistochemistry also indicate increased 
macrophage recruitment in irradiated tissues.  
 
Conclusion 
The study identifies dysregulated gene expression patterns in irradiated human breast adipose 
tissue and shows that AFT affects several pathways related to fibrosis. It contributes to the 
understanding of how AFT can ameliorate RIF and brings biological support to AFT as 
potential treatment against RIF. 
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Introduction 
 
With on-going improvements in cancer care, a growing population of survivors suffer from 
the late adverse effects after radiotherapy (RT), such as radiation-induced fibrosis (RIF), 
resulting in tissue scarring, induration and contracture. Clinical data mainly involve RIF after 
breast and head-neck cancer, where radiotherapy is commonly used and the impact is 
paramount on both functional and cosmetic outcome. RIF can adversely impact aesthetic 
outcomes after breast reconstruction resulting in asymmetry or deformity. Autologous fat 
transplantation (AFT) has gained significant popularity in the treatment of RIF and has 
shown, in clinical series, to improve the quality of irradiated skin and augment local volume 1.  
 
Recent studies describe improvements in RIF following AFT 2, 3. However, biological effects 
have mainly been studied in animal models4-6 and are still not fully understood. Efforts to 
explain radiation-induced fibrosis, for example, by genetic variation have remained largely 
inconclusive7. The authors have previously described global gene expression alterations in 
irradiated recipient vessels from free flap breast and head neck reconstructions8, 9, but there is 
a paucity of studies that have been able to describe gene expression patterns of the irradiated 
breast adipose tissue. Furthermore, the effect of AFT on gene expression profiles in humans 
is largely unknown. Therefore, a complete gene expression profiling strategy of unilaterally 
irradiated breasts has been undertaken and alterations following AFT have been studied, with 
the non-irradiated breast as a continuous control. Accordingly, we proceeded to identify 
shared and unique gene expression properties between irradiated and non-irradiated breast 
adipose tissue before and after AFT in humans. 
 
Material and Methods 
 
Patient selection 
From June 2009 to March 2015 breast cancer patients at the Department of Reconstructive 
Plastic surgery at Karolinska University Hospital in Stockholm, Sweden were invited to 
participate.  Women who had undergone previous breast surgery (breast conservation or 
mastectomy) and adjuvant radiotherapy, at least 12-months prior to recruitment, and who 
required AFT were included. Women with breast cancer recurrences and systemic 
inflammatory diseases were excluded. Informed consent was obtained from 30 patients.  
 
Autologous fat transplantation  
Fat was harvested using a dry technique, under general anaesthetic. In two patients tumescent 
liposuction was performed in one out of three AFT sessions due to a change in choice of 
method at the unit. The remaining parts of the AFT were performed identically. The fat was 
injected subcutaneously as previously described10. 
 
Human sample collection 
Synchronous, bilateral excision biopsies of fat tissue were taken from the irradiated and non-
irradiated breast from 30 women at two occasions (totally 104 biopsies) by a single surgeon. 
The preoperative biopsies were taken immediately before AFT and the postoperative biopsy, 
approximately one year after AFT. Biopsies from the irradiated breast were taken from a 
location where AFT was planned (ensuring the previous scar was not included) and in the 
control breast from the lower pole where the small scar would be less visible. Tissues were 
stored in either RNA-later® (Qiagen, Hilden, Germany) or in liquid nitrogen and stored at -
80°C for RNA purification and in formalin for immunohistochemistry. The samples were 
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registered in the Stockholm Medical Biobank (SMB). The study was approved by the Ethical 
review board in Stockholm (2008/484-31/2).  
 
RNA extraction  
Extraction of RNA was performed using the RNeasy Lipid Tissue Mini kit® (Qiagen, Hilden, 
Germany) as per the manufacturer’s protocol. RNA quality was analysed by micro capillary 
electrophoresis using an Agilent Bioanalyzer® (Agilent, Santa Clara, USA) with RNA 6000 
Pico Kit and Agilent 2200 TapeStation with RNA Screen Tape. The amount of RNA was 
determined by UV spectrophotometry with a NanoDrop® ND-1000 UV-Vis 
Spectrophotometer (Thermo Scientific, Waltham, USA). RNA samples were prepared from 
total RNA (100ng) for whole transcriptome expression analysis using the WT Plus reagent kit 
(Affymetrix, Santa Clara, USA). The kit generates amplified and biotinylated sense-strand 
DNA targets for hybridization to Gene Chip Sense Target Array plates. To be eligible for 
gene expression analysis (microarray), only samples achieving an RNA integrity number 
(RIN) of greater than 4.8 with a total available quantity of ≥ 100 ng were selected. This was 
carried out by the core facility for Bioinformatics and Expression Analysis (BEA) at 
Karolinska Institute. 
 
Gene expression profiling 
Microarrays were performed at two time-points where pre- and postoperative biopsies were 
evenly distributed between both time-points.  Gene expression profiling was performed using 
Affymetrix ®Human Gene 2.1 ST oligonucleotide microarrays, as previously described8. To 
identify pathways containing the dysregulated genes, data generated from Affymetrix ®
 
arrays were subjected to enrichment testing using Hallmark gene set enrichment analysis 
Molecular Signatures Database11, 12. The method examines whether differential expression of 
genetic pathways is higher than expected by chance. It identifies pathways that are affected 
(up or down regulated) by RT and AFT and provides biological understanding of the 
processes in the microenvironment. 
 
Analysis I - Gene expression alterations in fat after irradiation: 
In order to extract genes with expression patterns profoundly affected by radiotherapy, the 
3000 most up or down regulated genes of irradiated tissues compared to non-irradiated 
tissues were selected, representing the 10 % most dysregulated genes. The 10% threshold for 
selection was set in order to extract relevant genes only, but still with a sufficient number to 
be included for further genetic pathway analysis. A fold change (FC) was calculated for each 
of the 3000 transcripts by comparing gene expression levels of the irradiated with the non-
irradiated breast for each patient (FC pre) (Figure 1). Enriched pathways related to irradiation 
were then identified among the retrieved 3000 genes by using Hallmark analysis, comparing 
irradiated and non-irradiated preoperative biopsies with paired analysis for each patient.  
 
Analysis II - Gene expression reversal in irradiated fat after AFT: 
FC was calculated for the same 3000 transcripts as in Analysis I by comparing the 
postoperative biopsies of the irradiated and AFT treated breast with the non-irradiated control 
(FC post). Retrieved gene expression FCs could then be compared before and after AFT (FC 
pre vs. FC post) with paired t-test for each patient and transcript in order to detect variations 
caused by AFT with significance level set on 5 % (Figure 1). Genes that were significantly up 
or down regulated by irradiation preoperatively and then significantly reversed by AFT (FC 
close to 1) postoperatively were further analysed with Hallmark analysis to identify enriched 
pathways related to an effect caused by AFT. 
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Immunohistochemistry  
The tissues were routinely fixed in 10% buffered formalin, processed, and embedded in 
paraffin. Whole tissue sections were used for immunohistochemistry in all samples. Blocks 
were sectioned at a thickness of 3 µm. CD68 immunostaining13-15 (PG-M1 clone, Dako, 
Carpenteria, California) was performed by using a standard immunohistochemistry protocol. 
The antibody labels human monocytes and macrophages. Immunohistochemistry was carried 
out using an autostainer (Benchmark XT System, Ventana Medical Systems) per the 
manufacturer’s instructions. All glasses were then scanned and two independent, blinded 
collaborators used NDP.view2 for manual quantification of stained cells. The density (cells 
per mm2) ratio irradiated/non-irradiated was compared pre and post AFT. 
 
Statistics 
Students T-test was used to test differences between radiated and non-radiated biopsies (FC 
pre). Paired analysis with t-test was then performed to compare FC pre and FC post. Qlucore 
Omics Explorer (www.qlucore.com) and Microsoft excel was used to calculate students T-
test. No power calculation was performed since there are now previous data or measured 
effects of AFT to be based on or compare with. 
 
Results 
 
Patient selection 
A total of 30 patients were enrolled and 21 patients completed follow-up according to 
protocol. Three patients were excluded from further analysis (lack of biopsy pair or death), 
two patients refused follow-up biopsies and in four patients the preoperative biopsies were 
felt to be of insufficient quality and these patients were excluded from the protocol. RNA was 
purified in all collected biopsies (n=108). The biopsy pairs with better RNA quality were 
retained. Nine patients did not meet the requirements of RNA quality. Two samples were 
excluded due to insufficient quantity. Ten patients remained in the final analysis with both 
RNA quality and quantity that met the requirements for microarray analysis of the entire 
genome (Figure 1, Supplements). 
 
Patient demographics 
Median age at the time of AFT treatment was 53.7 years (range 31–70 years) among patients 
left for microarray analysis. The median radiation dose was at 50 Gy (range 46-60, one 
patient’s dose unknown). Median BMI at baseline was 24.2 (range 20.8-29.1) and had 
decreased to 22.9 at follow-up biopsy. One patient was a smoker and one patient was 
hypothyroid. Nine women had hormonal treatment for breast cancer. Median number of AFT 
treatments was 2.5 (range 1-4) with a median of total fat volume of 160 ml (range 82-322). 
Median time from last radiotherapy session to AFT was 163 weeks (range 56-740). Median 
time from AFT to follow-up biopsy was 62 weeks (range 45-119). There were no surgical 
complications (Table 1).  
 
Overview of expression data 
Due to two time-points for microarray analysis, array data were subjected to a “batch-
control” analysis showing a negligible effect of the temporal aspect, which further validated 
the reproducibility of the experiment. The investigated tissues from the non-irradiated control 
breasts were unchanged over time (from pre to post AFT), but divergent from the irradiated 
breast both before and after AFT. 
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Analysis I - Gene expression alterations in fat after irradiation: 
The analysis represents gene expression alterations caused by radiotherapy at a median time 
of 162.6 weeks following radiation exposure. Among these genes 45 pathways were 
significantly altered (p-value range 1.3×10-24 - 0.023) in the Hallmark analysis. The false 
discovery rate (FDR) q-values were low for all pathways (range 6.4×10-23-0.026). This higher 
gene set enrichment score was demonstrated for overlapping gene sets designated 
inflammation, fibrosis, cell adhesion and hypoxia. Epithelial mesenchymal transition (EMT) 
was the most dysregulated pathway followed by the interferon gamma (IFNγ) response 
(Figure 2). Connective tissue growth factor (CTGF) was one of the most dysregulated genes 
(p<0.001) and furthermore present in the EMT pathway. The 100 most dysregulated genes 
are given in supplement Table 1. 
 
Analysis II - Gene expression reversal in irradiated fat after AFT: 
The analysis showed that 575 (19 %) of the 3000 genes analysed in Analysis I, had 
significantly less variation between the respective sides post AFT compared to pre AFT (FC 
pre vs. FC post). AFT significantly altered FC values for CTGF (p=0.004). Hallmark analysis 
of the 575 genes showed 13 enriched pathways (all previously among the enriched gene sets 
in Analysis I) (p-value range 1.0×10-4-0.013; FDR range 5.1×10-4 - 0.05). Interferon gamma 
(IFNγ) was most affected by AFT (p=1.1×10-5) followed by hypoxia (p=6.4×10-5) (Figure 2, 
complete list in supplements Table 2). Genes involved in the IFNγ and hypoxia pathways are 
displayed in Figure 3. 
 
Immunohistochemistry  
Out of the ten patients, one lacked preoperative biopsy for immunohistochemistry and four 
had not satisfying tissue or stain quality for cell counting in one of four biopsies. Biopsies of 
the remaining five patients were examined by two blinded evaluators. In all patients except 
one, the macrophage ratio (irradiated/non-irradiated pre vs. irradiated/non-irradiated post) 
was lowered after AFT (Figure 4). 
 
Discussion 
  
The current study shows that AFT can alter radiotherapy-induced gene expression patterns in 
humans. By using a global gene expression strategy, with enrichment testing, it was 
demonstrated that this effect was most prominent in pathways involved in inflammation, 
fibrosis and hypoxia. The prospective setting with validated internal controls of the patient´s 
non-irradiated breast provides a good opportunity to unravel the underlying mechanisms 
associated with AFT in irradiated humans. The study also includes a global analysis of genes 
that are dysregulated by irradiation in human adipose tissue, which to our knowledge has not 
been described previously. However, the findings are equally supported by earlier studies in 
other tissues and/or species. The initial finding of the most enriched pathways in the 
irradiated breast before AFT was EMT, previously known to be activated by irradiation in 
other tissues7, 16-18. EMT has also been shown to be activated by CTGF19, which was 
furthermore one of the most highly expressed genes after irradiation in the current study. In a 
recent review by Kumar et al about AFT in radiation-induced fibrosis17, one-third of studies 
recognized CTGF to be highly involved in fibrotic cascades, and, three studies suggested 
hypoxia as the stimulus for the fibrotic response. However, none of these studies included in 
this review were in human tissues. Other recent work by Khan et al has shown that reducing 
CTGF gene expression using a lentivirally-delivered, small hairpin RNA, in vivo, can protect 
flap tissues from fibrosis post-radiotherapy, which further supports a pivotal role for CTGF in 
this context. 20. Therapeutic studies using a monoclonal antibody targeting CTGF have also 
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shown reductions in the fibrotic burden in RT-induced pulmonary fibrosis21. Our own 
findings, in this study, of highly dysregulated CTGF gene expression in human breast adipose 
tissue is therefore a highly relevant contribution to the literature.  
 
The second most enriched pathway in the analysis of AFT treatment effects (Analysis II) was 
hypoxia, where a majority of the involved, dysregulated genes reached FC values closer to 1 
after AFT (1.0 = no difference between non-irradiated and previously irradiated breasts). This 
is particularly interesting since hypoxia22 is regarded as a hallmark of radiation induced 
fibrosis23 and caused by a post-radiation vasculopathy as shown by others, and, us8, 24. Tissue 
hypoxia is associated with perivascular matrix deposition and the induction of extracellular 
matrix synthesis17, 25. Luan et al and Garza et al showed less hypovascularity in previously 
irradiated skin after AFT in mice6, 26. In addition, Garza et al also showed decreased dermal 
thickening and collagen deposition. Rigotti et al treated 20 patients with severe-to-
irreversible adverse effects of irradiation (LENT-SOMA 3-4) with autologous purified fat 
cell transplantation with all but one patient showing a significant improvement in symptoms. 
Electron microscopy prior to AFT showed patterns consistent with radiation-induced 
ischaemic lesions and scleroderma and, post-operatively, they observed a gradual 
improvement and normalisation of the microcirculation with greater hydration and less 
fibrosis.  They also observed increased macrophage influx post-RT and reported a reduction 
in this post-AFT. These reports support the validity of our findings that AFT reduced hypoxia 
and fibrosis pathway expression, together with reduced macrophage density, and contributes 
to a biological explanation for the clinical success of AFT.  
 
Interestingly, IFNγ response, known to be associated with inflammatory responses to ionizing 
radiation22, 27, 28, was the second most enriched pathway in analysis of radiation effects 
(Analysis I) and the most enriched pathway in analysis of AFT treatment effects (Analysis II). 
Inflammatory cytokines play a pivotal role in the development of fibrosis. The current study 
clearly shows that both innate and adaptive inflammatory networks are activated years after 
radiotherapy in adipose tissue. This is in itself a valuable finding since there is a paucity of 
studies on the effects of radiotherapy in human adipose tissue. Poglio et al could for instance 
show a severe decrease in proliferating cells, as well as a significant increase in apoptotic 
cells in inguinal fat pads, following radiation exposure in mice. Decrease in the proliferation 
and differentiation capacities of non-hematopoietic progenitors was also observed following 
irradiation. The study indicates that subcutaneous adipose tissue is very sensitive to 
irradiation, leading to a profound alteration of its developmental potential. The authors 
suggest that AFT with mesenchymal stem cells may have a role to reverse the injury as a 
potential treatment for RIF in skin and subcutaneous fat29.  A trend towards reduced 
macrophage density was observed in irradiated adipose tissue after AFT in the current study. 
We encourage further in depth studies looking at the specific role of macrophages in adipose 
tissue after irradiation and AFT since macrophages are known to be master regulators of 
inflammation and fibrosis30. 
 
Limitations of the study need to be acknowledged. The global gene expression strategy 
describes several pathways involved in radiation injury as well as the effect of AFT on 
irradiated tissues, but does not include in depth analysis of a specific mechanism. However, 
the study was intentionally designed to unravel the main networks activated in a wider 
perspective. The number of patients may be regarded as a limitation, but the internal control 
of the non-irradiated breast both before and after AFT enables paired analysis and increases 
the power significantly. This is in line with previous studies performed on conduit vessels 
with similar design and sample size8, 24. 
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Taken together, it has been studied how radiotherapy can cause alterations in global gene 
expression patterns by comparing irradiated and non-irradiated adipose tissue harvested from 
the same patient at the same time, and thereby eliminating inter-individual factors. Long-term 
alterations in the described gene expression patterns following AFT to the irradiated breast 
have furthermore been studied, still with a simultaneous control biopsy from the contralateral 
non-irradiated breast. Our results clearly show enriched gene expression pathways associated 
with sustained inflammation, fibrosis and hypoxia several years after radiation exposure in 
the irradiated breast compared to the control. It has further been shown that AFT attenuated 
radiation-induced dysregulated gene expression patterns related to the same pathways. We 
believe that effect caused by AFT on inflammation and hypoxia, together with the 
identification of a consistent and rather uniform pattern of differentially expressed genes 
between radiated and non-radiated breasts, have generated new perspectives for future 
research. The study has also generated biological support in humans for the potential of AFT 
to be used to ameliorate RIF. We therefore welcome further studies regarding biological 
effects and clinical outcome following AFT. 
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Tables and Figures 
 
	
Figure 1. A global gene expression strategy was conducted to unravel altered pathways. 
Analysis I (RT vs. no RT): Initial selection of the 3000 most differentially expressed genes in 
irradiated adipose tissue compared to internal controls. Analysis II (No RT vs. RT vs. RT + 
AFT): The effect of AFT was determined by comparison of fold change values before and 
after AFT (Fold change=1 represents no difference between the irradiated and non irradiated 
breast). FC=Fold change, -RT=non-irradiated (control), +RT=irradiated, 
+RT+AFT=irradiated and AFT treated 
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Previous	breast	surgery		(n)	 10	
	Mastectomy*	 4	
	Mastectomy	+	delayed	reconstruction	with	expander	prosthesis	 1	
	BCS	 5	
	Time	from	irradiation	to	preop	biopsy/first	AFT	(mos)	 37.4	 12.9-170.2	
Radiation	dose	(Gy)**	 50	 46-60	
Age	at	preop	biopsy	and	first	AFT	(y)	 53.7	 31.3-70	
Fat	injected	(ml)	 160.0	 82-322	
Number	of	treatments	(n)	 2.5	 1-4	
BMI	first	biopsy	(kg/m2)	 24.2	 20.8-29.1	
BMI	follow-up	biopsy	(kg/m2)	 22.9	 20.5-28.8	
Time	from	AFT	to	postop	biopsy	(mos)	 14.2	 10.3-27.3	
Table 1. Patient characteristics (n=10) Median and range are given for continuous values. 
AFT=autologous fat transplantation, BMI=body mass index, RT=radiotherapy *The patients 
underwent delayed breast reconstruction with expander prosthesis between pre- and 
postoperative biopsies **One patients radiation dose is not known 
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Figure 2. Significantly enriched pathways after Hallmark analysis, sorted by increasing p-
values (-log(p)), showing the most significantly altered gene expression patterns for Analysis 
I (n=45) and II (n=13). The blue bars (Analyse I) shows –log(p) for difference in gene 
expression between preoperative (irradiated vs. non-irradiated) biopsies. The red bars shows 
–log(p) for difference between fold change fore preoperative and postoperative biopsies. The 
dotted vertical line shows the 0.05 significance level.*Differentially expressed pathways 
significantly affected by both irradiation and AFT. 
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Figure 3: Effect of AFT on mRNA expression patterns for individual genes involved in 
interferon gamma response and hypoxia pathways. The Y-axes shows fold change (FC). FC 
1.0 indicates no difference in gene expression level between the compared biopsy pair 
(irradiated breast compared to the non-irradiated control). Deviation from FC 1.0 means that 
the gene is dysregulated (up or down regulated) compared to the non-radiated control breast. 
Blue box: comparison of gene expression before AFT. Pink box: comparison of gene 
expression after AFT. 
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Figure 4. Immunohistochemistry for CD68 staining. A) Non-irradiated, pre AFT B) 
Irradiated, pre AFT C) Non-irradiated, post AFT D) Irradiated, post AFT Arrows indicate 
macrophages. (scale = 250 and 50 µm). Graph: Cell density (cells/mm2) ratio of CD68+ cells 
in irradiated and non-irradiated tissues, before and after AFT. Four out of five patient had a 
lowered ratio after AFT treatment.  
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Kliniken för Rekonstruktiv Plastikkirurgi 
Karolinska Universitetssjukhuset 
Stockholm 
 
 
 
Enkät för utvärdering före och efter 
bröstrekonstruktion  
 
 
 
 
Följande frågeformulär är framtaget för att öka kunskapen om effekterna 
av bröstrekonstruktion med eller utan föregående fettransplantation. 
 
Målet är att denna kunskap i framtiden skall förbättra omhändertagandet 
för kvinnor som genomgår bröstrekonstruktion. 
 
 
Frågeformulären hanteras konfidentiellt och är kodade så att inga 
personuppgifter eller namn finns kopplade till det enskilda 
frågeformuläret.  
 
 
Tack för din medverkan! 
 
 
 
 
 
 
 
Inkeri Schultz    Marie Wickman           
Bitr överläkare, Med dr Divisionschef, Professor       
   
Enkät brek m/u lipo 101219 IS 2 
Enkät bröstrekonstruktion 
 
 
 
Svarsdatum:............................................................ 
 
Namn:..................................................................... 
 
 
 
 
Nedanstående frågor handlar om känselförmåga och känselupplevelser i 
brösten/bröstkorgen och besvaras genom att Du ringar in den siffra i skalan 1 - 7 som 
bäst stämmer överens med hur Du upplever känseln i dina bröst för närvarande. 
 
 
 
 
 
 
1. Hurdan är Din förmåga att känna beröring på bröstens hud? 
 
Höger: Känner normalt   1     2     3     4     5     6     7    Nedsatt känsel 
Vänster: Känner normalt   1     2     3     4     5     6     7    Nedsatt känsel 
 
2. Hurdan är Din förmåga att känna sexuella känslor i brösten? 
 
Höger: Känner normalt   1     2     3     4     5     6     7     Nedsatt känsel 
Vänster: Känner normalt   1     2     3     4     5     6     7     Nedsatt känsel 
 
3. Har Du värk/smärta i brösten/bröstregionen? 
Höger: Ja, varje dag    1     2     3     4     5     6     7     Nej, aldrig  
Vänster: Ja, varje dag    1     2     3     4     5     6     7     Nej, aldrig 
 
 
   
Enkät brek m/u lipo 101219 IS 3 
Följande frågor berör sexualitet och är känsliga och personliga, men ändå viktiga att 
ställa för att få kunskap om huruvida dessa områden påverkas av bröstoperationen. 
Ringa in det svarsalternativ som Du tycker stämmer bäst in på Dig 
 
 
4. Har Dina bröst stor betydelse i din sexualitet? 
Inte alls  Lite  Ganska mycket  Mycket 
 
5. Känner Du Dig sexuellt oattraktiv på grund av Dina bröst? 
Inte alls  Lite  Ganska mycket  Mycket 
 
6. Har Du svårt att se Dig själv naken p g a Dina bröst? 
Inte alls  Lite  Ganska mycket  Mycket 
  
Om Du har en partner, vänligen besvara även följande fråga:  
7. Har Du svårt att visa Dig naken inför Din partner? 
Inte alls  Lite  Ganska mycket  Mycket 
 
 
Följande frågor besvaras genom att Du ringar in den siffra i skalan 1 - 7 som bäst 
stämmer överens med vad Du nu tycker om utseendet av dina bröst. 
 
 
 
BRÖSTENS STORLEK 
 
8. Vad anser Du om storleken på Dina bröst?   
Höger:  För litet  1 2 3 4 5 6 7  För stort 
Vänster:  För litet  1 2 3 4 5 6 7  För stort 
 
 
9. Är brösten lika i storlek?  
Mycket olika  1 2 3 4 5 6 7       Mycket lika 
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BRÖSTENS FORM 
 
10. Vad anser Du om formen på Dina bröst? 
Höger: Mycket ful   1 2 3 4 5 6 7       Mycket fin 
Vänster: Mycket ful   1 2 3 4 5 6 7       Mycket fin 
 
 
 
11. Är brösten lika i formen? 
Mycket olika  1 2 3 4 5 6 7       Mycket lika 
 
 
BRÖSTENS KONSISTENS/MJUKHET 
 
12. Vad anser Du om mjukheten i Dina bröst? 
Höger: Mycket hårt  1 2 3 4 5 6 7       Mycket 
              mjukt 
 
Vänster: Mycket hårt  1 2 3 4 5 6 7       Mycket 
              mjukt
   
 
BRÖSTENS UTSEENDE 
 
13. Är du nöjd med utseendet av Dina bröst? 
 
Höger: Inte alls nöjd  1 2 3 4 5 6 7 Mycket nöjd 
Vänster: Inte alls nöjd  1 2 3 4 5 6 7 Mycket nöjd 
 
 
14. Vad anser Du om bröstens utseende när Du har kläder på dig? 
Höger: Mycket fult  1 2 3 4 5 6 7 Mycket fint 
Vänster  Mycket fult  1 2 3 4 5 6 7 Mycket fint 
   
15. Vad anser Du om bröstens utseende när Du har badkläder/BH på dig?   
Höger: Mycket fult  1 2 3 4 5 6 7 Mycket fint 
Vänster  Mycket fult  1 2 3 4 5 6 7 Mycket fint 
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16. Vad anser Du om bröstens utseende när Du är naken? 
Höger: Mycket fult  1 2 3 4 5 6 7 Mycket fint 
Vänster  Mycket fult  1 2 3 4 5 6 7 Mycket fint 
 
 
17. Vad anser Du om bröstens utseende när Du har badkläder/BH på dig? 
 
Höger: Mycket fult  1 2 3 4 5 6 7 Mycket fint 
Vänster  Mycket fult  1 2 3 4 5 6 7 Mycket fint 
 
18. Om Du har ärr efter tidigare bröstcanceroperation - vad anser Du om 
ärrets/ärrens utseende? 
 
Höger: Mycket fult  1 2 3 4 5 6 7 Mycket fint 
Vänster  Mycket fult  1 2 3 4 5 6 7 Mycket fint 
 
BLANDADE FRÅGOR 
 
19. Har Du svårt att hitta en BH som passar Dina bröst? 
 
  Mycket svårt  1 2 3 4 5 6 7       Inte alls 
              svårt 
 
 
20. Påverkar Dina bröst Din vilja att bada i offentliga miljöer (simhall, badstrand etc.)  
eller delta i gymnasik och liknade aktiviteter? 
  
Negativt  1 2 3 4 5 6 7  Positivt 
 
 
 
           
Det är viktigt att du besvarat samtliga frågor i formuläret, fråga gärna vid 
oklarheter.  
 
 
Tack så mycket för din medverkan! 
